<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>f53483exv2w1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv2w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;2.1</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<DIV style="width: 100%; border-bottom: 3px double #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">among:

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>LEO Pharma A/S,</B></FONT>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Plant Acquisition Sub, Inc.,</B></FONT><BR>
a Delaware corporation; and

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Peplin, Inc.</B></FONT><BR>
a Delaware corporation

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV><BR>
Dated as of September&nbsp;2, 2009<BR>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV style="width: 100%; border-bottom: 3px double #000000; font-size: 1px">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SECTION 1. DESCRIPTION OF TRANSACTION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.1 Merger of Merger Sub into the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.2 Effects of the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.3 Closing; Effective Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.4 Certificate of Incorporation and Bylaws; Directors and Officers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.5 Conversion of Shares, Options and Warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.6 Payment Fund</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.7 Payment Procedures</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.8 Termination of Payment Fund</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.9 Closing of the Company&#146;s Transfer Books</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.10 Lost Certificates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.11 Withholding Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.12 Further Action</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.1 Subsidiaries; Due Organization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.2
Capitalization, Etc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.3 ASX Filings; SEC Filings; Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.4 Absence of Changes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.5 Title to Assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.6 Real Property; Leasehold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.7 Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.8 Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.9 Compliance with Legal Requirements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.10 Certain Business Practices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.11 Governmental Authorizations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.12 Tax Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.13 Employee and Labor Matters; Benefit Plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.14 Transactions with Affiliates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.15 Legal Proceedings; Orders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.16 Regulatory Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.17 Environmental Compliance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.18 Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.19 Authority</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.20 Non-Contravention; Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.21 Information Supplied</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.22 Fairness Opinion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.23 Financial Advisor</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.24 Delaware Section&nbsp;203</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.25 Full Disclosure</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.26 No Other Representations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SECTION 3. REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.1 Due Organization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.2 Legal Proceedings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.3 Authority</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.4 Non-Contravention; Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.5 Information Supplied</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.6 Financial Advisor</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.7 Ownership of Company Common Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.8 No Prior Merger Sub Operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.9 Sufficient Funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.10 No Other Representations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SECTION 4. CERTAIN COVENANTS OF THE PARTIES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.1 Access and Investigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.2 Operations Before Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.3 No Solicitation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SECTION 5. ADDITIONAL COVENANTS OF THE PARTIES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.1 Company Proxy Statement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.2 Company Stockholders&#146; Meeting</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.3 Company Options and Company Warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.4 Employee Benefits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.5 Indemnification of Officers and Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.6 Regulatory Approvals and Related Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.7 Confidentiality; Disclosure</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.8 CHESS Depositary Interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.9 Section&nbsp;16 Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.10 Resignation of Officers and Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.11 Stockholder Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.12 Employee Retention</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SECTION 6. CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.1 Accuracy of Company Representations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.2 Performance of Covenants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.3 Company Stockholder Approval</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.4 Noncompetition Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.5 Company Officers&#146; Certificate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.6 Regulatory Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.7 No Restraints</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.8 No Governmental Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.9 No Company MAE</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.10 Employee Retention</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SECTION 7. CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.1 Accuracy of Parent and Merger Sub Representations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.2 Performance of Covenants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.3 Company Stockholder Approval</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.4 Parent Officer&#146;s Certificate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.5 HSR Waiting Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.6 No Restraints</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SECTION 8. TERMINATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.1 Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.2 Effect of Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.3 Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.4 Termination Fee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SECTION 9. MISCELLANEOUS PROVISIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.1 Amendment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.2 Extension; Waiver</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.3 No Survival of Representations and Warranties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.4 Entire Agreement; Counterparts; Exchanges by Facsimile
or Electronic Delivery</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.5 Applicable Law; Jurisdiction</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.6 Attorneys&#146; Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.7 Assignability; No Third Party Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.8 Notices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.9 Severability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.10 Remedies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">57</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.11 Construction</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">57</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXECUTION VERSION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This<FONT style="font-variant: SMALL-CAPS"> <B>Agreement and Plan of Merger </B></FONT>(this &#147;<B><I>Agreement</I></B>&#148;) is made and entered into as of
September&nbsp;2, 2009, by and among<FONT style="font-variant: SMALL-CAPS"> <B>LEO Pharma A/S</B></FONT> (&#147;<B><I>Parent</I></B>&#148;), <FONT style="font-variant: SMALL-CAPS"><B>Plant Acquisition Sub,
Inc.</B></FONT>, a Delaware corporation and a wholly owned subsidiary of Parent (&#147;<B><I>Merger Sub</I></B>&#148;), and
<FONT style="font-variant: SMALL-CAPS"><B>Peplin, Inc.</B></FONT>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;). Certain capitalized terms used in
this Agreement are defined in <U><B>Exhibit&nbsp;A</B></U>.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Recitals</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>A.&nbsp;</B>Parent, Merger Sub and the Company intend to effect a merger of Merger Sub with and into
the Company in accordance with this Agreement and the DGCL (the &#147;<B><I>Merger</I></B>&#148;). Upon consummation of
the Merger, Merger Sub will cease to exist, and the Company will become a wholly owned subsidiary
of Parent (or such Affiliate of Parent as Parent may designate).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>B.&nbsp;</B>The respective boards of directors of Parent, Merger Sub and the Company have unanimously
approved this Agreement and the Merger and have deemed the Merger to be advisable and fair to, and
in the best interests of, their respective corporations and stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>C.&nbsp;</B>In order to induce Parent to enter into this Agreement and cause the Merger to be
consummated, contemporaneously with the execution and delivery of this Agreement: (i)&nbsp;certain
stockholders of the Company are executing voting agreements in favor of Parent (the &#147;<B><I>Voting
Agreements</I></B>&#148;); and (ii)&nbsp;certain stockholders of the Company are executing Noncompetition Agreements
in favor of Parent and the Company (the &#147;<B><I>Noncompetition Agreements</I></B>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Agreement</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties to this Agreement, intending to be legally bound, agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;1.</B>
<FONT style="font-variant: SMALL-CAPS"><B>Description of Transaction</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.1 Merger of Merger Sub into the Company</B>. Upon the terms and subject to the conditions set
forth in this Agreement, and in accordance with the DGCL, at the Effective Time (as defined in
<U>Section&nbsp;1.3</U>), Merger Sub shall be merged with and into the Company. By virtue of the
Merger, at the Effective Time, the separate existence of Merger Sub shall cease and the Company
shall continue as the surviving corporation in the Merger (the &#147;<B><I>Surviving Corporation</I></B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.2 Effects of the Merger</B>. The Merger shall have the effects set forth in this Agreement and
in the applicable provisions of the DGCL.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.3 Closing; Effective Time</B>. The consummation of the Merger (the &#147;<B><I>Closing</I></B>&#148;) shall take place
remotely via the exchange of signature pages, on a date to be designated by Parent which shall be
not more than three Business Days after the satisfaction or
waiver of the last to be satisfied or waived of the conditions set forth in <U>Sections&nbsp;6</U>
and <U>7</U> (other than conditions that by their nature are only satisfied as of the Closing, but
subject to the satisfaction or waiver of each of such conditions), or such other Business Day as
the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and Parent may mutually agree. The date on which the Closing actually takes place is
referred to as the &#147;<B><I>Closing Date</I></B>.&#148; Subject to the provisions of this Agreement, the Company shall
execute a certificate of merger in the form attached hereto as <U><B>Exhibit&nbsp;B</B></U> and concurrently
with or as soon as practicable following the Closing the Company shall cause such certificate to be
filed with the Secretary of State of the State of Delaware. The Merger shall become effective at
the time such certificate of merger is filed with the Secretary of State of the State of Delaware
or at such later time as Parent and the Company may agree and specify in such certificate of
merger. The time as of which the Merger becomes effective is referred to as the &#147;<B><I>Effective Time</I></B>.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.4 Certificate of Incorporation and Bylaws; Directors and Officers</B>. At the Effective Time,
unless otherwise determined by Parent prior to the Effective Time:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>the certificate of incorporation of the Surviving Corporation shall be amended to conform
to the certificate of incorporation of Merger Sub as in effect immediately prior to the Effective
Time, until amended in accordance with applicable Legal Requirements; <I>provided, however</I>, that at
the Effective Time, Article&nbsp;I of the certificate of incorporation of the Surviving Corporation
shall be amended to read: &#147;The name of the corporation is Peplin, Inc.&#148;;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>the bylaws of the Surviving Corporation shall be amended and restated as of the Effective
Time to conform to the bylaws of Merger Sub as in effect immediately prior to the Effective Time;
<I>provided, however</I>, that at the Effective Time, Article&nbsp;I of the bylaws of the Surviving Corporation
shall be amended to provide that the name of the Surviving Corporation shall be Peplin, Inc.; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>the directors of the Surviving Corporation immediately after the Effective Time shall be
the respective individuals who are directors of Merger Sub immediately prior to the Effective Time
and the officers of the Surviving Corporation immediately after the Effective Time shall be the
respective individuals who are officers of Merger Sub immediately prior to the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.5 Conversion of Shares, Options and Warrants.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>At the Effective Time, by virtue of the Merger and without any further action on the part
of Parent, Merger Sub, the Company or any Company Stockholder:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i) </B>any shares of Company Common Stock held by the Company or by any wholly owned Subsidiary
of the Company (or held in the Company&#146;s treasury) immediately prior to the Effective Time shall be
canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange
therefor; for the avoidance of doubt, shares of Company Common Stock held in escrow by JPMorgan
Chase Bank, N.A. (&#147;<B><I>JPMorgan</I></B>&#148;) pursuant to that certain Agreement and Plan of Reorganization, dated
as of June&nbsp;9, 2008, by and among the Company, West Acquisitions Corporation, Neosil, Inc. and
Nicholas J. Simon, III (the &#147;<B><I>Neosil Merger Agreement</I></B>&#148;) and that certain Escrow Agreement, dated as
of October&nbsp;16, 2008, by and among the Company, Neosil, Inc., Nicholas Simon III and JPMorgan
(the &#147;<B><I>Neosil Escrow Agreement</I></B>&#148;), shall not be deemed to be held by the Company or by any
wholly owned subsidiary of the Company;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>any shares of Company Common Stock held by Parent, Merger Sub or any other wholly owned
Subsidiary of Parent immediately prior to the Effective Time shall be canceled and retired and
shall cease to exist, and no consideration shall be delivered in exchange therefor;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>except as provided in clauses &#147;(i)&#148; and &#147;(ii)&#148; above and subject to <U>Section
1.5(b),</U> <U>Section&nbsp;1.5(c)</U> and <U>Section&nbsp;1.5(d)</U>, each share of Company Common Stock
outstanding immediately prior to the Effective Time (including any shares of Company Common Stock
issued upon exercise of Company Options before the Effective Time but excluding any Dissenting
Shares) shall be converted into the right to receive $16.99 in cash, without interest (the &#147;<B><I>Per
Share Merger Consideration</I></B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>each outstanding and unexercised Company Option shall be treated as set forth in
<U>Section&nbsp;5.3(a)</U>;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(v)&nbsp;</B>each outstanding and unexercised Company Warrant shall be treated as set forth in
<U>Section&nbsp;5.3(b)</U>;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vi)&nbsp;</B>each share of Company Common Stock held in escrow by JPMorgan pursuant to the Neosil
Merger Agreement and the Neosil Escrow Agreement shall be converted into the Per Share Merger
Consideration, but pursuant to Section&nbsp;9 of the Neosil Escrow Agreement, such Per Share Merger
Consideration shall remain in escrow with JPMorgan, until released pursuant to the terms of, and
subject to the conditions of, the Neosil Merger Agreement and Neosil Escrow Agreement; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vii)&nbsp;</B>each share of the common stock, par value $0.001 per share, of Merger Sub outstanding
immediately prior to the Effective Time shall be converted into one share of common stock of the
Surviving Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>If, during the period commencing on the date of this Agreement and ending at the Effective
Time, the outstanding shares of Company Common Stock are changed into a different number or class
of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse
stock split, consolidation of shares, reclassification, recapitalization or other similar
transaction, or if the Company declares a stock dividend during such period, or a record date with
respect to any such event occurs during such period, then the Per Share Merger Consideration shall
be adjusted to the extent appropriate to provide the same economic effect as contemplated by this
Agreement prior to such action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>Notwithstanding anything in this Agreement to the contrary, any Dissenting Shares shall
not be converted into the right to receive the Per Share Merger Consideration provided for in
<U>Section&nbsp;1.5(a)(iii)</U>, but shall instead be converted into the right to receive such
consideration as may be determined to be due with respect to any such Dissenting Shares pursuant to
the applicable provisions of the DGCL. Each holder of Dissenting Shares who, pursuant to the
applicable provisions of the DGCL, becomes entitled to payment thereunder for such shares shall
receive payment therefor in accordance with Section&nbsp;262 of the DGCL (but
only after the value therefor has been agreed upon or finally determined pursuant to such
provisions). If, after the Effective Time, any Dissenting Shares shall lose their status as
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dissenting Shares, then any such shares shall immediately be converted into the right to receive
the Per Share Merger Consideration as if such shares never had been Dissenting Shares, and Parent
shall issue and deliver to the holder thereof, at (or as promptly as reasonably practicable after)
the satisfaction of the applicable conditions set forth in <U>Section&nbsp;1.7</U>, the total amount of
cash consideration to which such holder would be entitled in respect thereof under <U>Section
1.5(a)(iii)</U> as if such shares never had been Dissenting Shares (and all such cash shall be
deemed for all purposes of this Agreement to have become deliverable to such holder pursuant to
<U>Section&nbsp;1.5(a)(iii)</U>). The Company shall give Parent (i)&nbsp;prompt notice of any demands for
appraisal received by the Company, withdrawals of such demands, and any other instruments served
pursuant to the applicable provisions of the DGCL and received by the Company, and (ii)&nbsp;the right
to participate in all negotiations and proceedings with respect to demands for appraisal under the
applicable provisions of the DGCL. The Company shall not, except with the prior written consent of
Parent, voluntarily make any payment or offer to make any payment with respect to, or settle or
offer to settle, any claim or demand in respect of any Dissenting Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>In the event there is a breach by the Company of any of the representations of the Company
in <U>Section&nbsp;2.2(a)</U> or <U>Section&nbsp;2.2(c)</U>, and as a result of the facts giving rise to
such breach, the aggregate amounts payable under <U>Section&nbsp;1.5(a)</U> and <U>Section&nbsp;5.3</U> or
otherwise in respect of any other equity securities of the Company outstanding immediately prior to
the Effective Time that are entitled to receive consideration as a consequence of the Merger would
exceed the sum of (i) $287.5&nbsp;million plus (ii)&nbsp;the aggregate exercise price of any Company Options
or Company Warrants exercised between the date of this Agreement and the Effective Time, to the
extent actually received by the Company (such sum, the &#147;<B><I>Maximum Aggregate Consideration</I></B>&#148;), then
Parent at its election may adjust the Per Share Merger Consideration to be an amount determined as
follows: the sum of (1)&nbsp;the Maximum Aggregate Consideration plus (2)&nbsp;the aggregate exercise price
of all Company Options and Company Warrants outstanding and unexercised immediately prior to the
Effective Time, such sum then divided by the sum of the following: (X)&nbsp;the aggregate number of
shares of Company Common Stock (other than shares held by Parent, Company, Merger Sub or any other
wholly owned Subsidiary of Parent or the Company) outstanding immediately prior to the Effective
Time; (Y)&nbsp;the aggregate number of shares of Company Common Stock issuable pursuant to all Company
Options and Company Warrants outstanding immediately prior to the Effective Time (assuming no net
exercise thereof); and (Z)&nbsp;the number (based on the number of shares of Company Common Stock to
which it is equivalent, calculated on a treasury stock method) of any other rights to acquire
Company Common Stock, or any securities that are convertible into or exchangeable for, Company
Common Stock, outstanding immediately prior to the Effective Time. For purposes of the preceding
sentence, the effect of any change to the rate of exchange between Australian Dollars and United
States Dollars after the date of this Agreement shall be disregarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.6 Payment Fund</B>. On or prior to the Closing Date, Parent shall select a reputable national
bank or trust company reasonably acceptable to the Company (the &#147;<B><I>Paying Agent</I></B>&#148;) to act as paying
agent under this Agreement for the purpose of distributing the aggregate cash consideration
distributable pursuant to <U>Section&nbsp;1.5(a)(iii)</U> and <U>Section&nbsp;5.3(b)</U> (the &#147;<B><I>Cash
Consideration</I></B>&#148;). At or prior to the Effective Time, Parent shall deposit with the Paying Agent,
for the benefit of the holders of shares of Company Common Stock (other than Dissenting
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Shares) and holders of Company Warrants outstanding immediately prior to the Effective Time, the
Cash Consideration (the &#147;<B><I>Payment Fund</I></B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.7 Payment Procedures</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>As soon as practicable after the Effective Time, Parent shall cause the Paying Agent to
mail to each holder of record of a certificate or certificates which immediately prior to the
Effective Time represented outstanding shares of Company Common Stock and each holder of a Company
Warrant immediately prior to the Effective Time (such certificates and Company Warrants,
collectively, the &#147;<B><I>Certificates</I></B>&#148;), and each holder of uncertificated shares of Company Common Stock
represented by book-entry (including Share CDIs held on an issuer-sponsored subregister or CHESS
subregister, the &#147;<B><I>Book-Entry Shares</I></B>&#148;): (i)&nbsp;a letter of transmittal which shall specify that
delivery shall be effective, and risk of loss and title to the Certificates or Book Entry Shares
shall pass, only upon delivery of the Certificates to the Paying Agent, and which letter shall be
in customary form and have such other provisions as Parent shall reasonably specify; and (ii)
instructions for effecting the surrender of such Certificates (or affidavits of loss in lieu
thereof) or Book-Entry Shares in exchange for such holder&#146;s applicable portion of the Cash
Consideration. Upon surrender of a Certificate (or affidavits of loss in lieu thereof), or in the
case of Book-Entry Shares, in adherence with the applicable procedures set forth in the letter of
transmittal, to the Paying Agent, together with such letter of transmittal and such other documents
as may be reasonably required by the Paying Agent or Parent, duly executed and completed in
accordance with the instructions to the letter of transmittal, and such other documents as may be
reasonably required by the Paying Agent or pursuant to such instructions, the holder of such
Certificate or Book-Entry Shares shall be entitled to receive in exchange therefor the applicable
portion of the Cash Consideration and the Certificates or Book-Entry Shares so surrendered shall
forthwith be cancelled. Until surrendered as contemplated by this <U>Section&nbsp;1.7(b)</U>, each
Certificate shall be deemed, from and after the Effective Time, to represent only the right to
receive Cash Consideration as contemplated by <U>Section&nbsp;1.5</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>No interest will be paid or will accrue on the Cash Consideration. In the event of a
transfer of ownership of Company Common Stock or Company Warrant which is not registered in the
transfer records of the Company, the applicable portion of the Cash Consideration otherwise payable
with respect thereto shall be payable to such transferee if the Certificate representing such
Company Common Stock or Company Warrant is presented to the Paying Agent, accompanied by all
documents reasonably required to evidence and effect such transfer and to evidence that any
applicable stock transfer taxes have been paid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.8 Termination of Payment Fund</B>. Any portion of the Payment Fund that remains undistributed
to the holders of Certificates and Book-Entry Shares on the first anniversary of the Effective Time
shall be delivered to Parent, and any holder of Certificates or Book-Entry Shares who has not
complied with the provisions of this <U>Section&nbsp;1</U> as of that time shall thereafter look only
to Parent for the applicable portion of the Cash Consideration with respect to the shares of
Company Common Stock and Company Warrants formerly represented thereby, and Parent shall, upon the
request of any such holder of Certificates or Book-Entry Shares, promptly pay to such Persons the
applicable portion of the Cash Consideration to which
such Persons is entitled. Any such portion of the Payment Fund remaining unclaimed by a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">holder of Certificates or Book-Entry Shares on the date that is five years after the Effective Time
(or such earlier date immediately prior to such time as such amounts would otherwise escheat to or
become property of any Governmental Body pursuant to applicable Legal Requirements) shall, to the
extent permitted by applicable Legal Requirements, become the property of Parent free and clear of
any claims or interest of any person previously entitled to that portion of the Payment Fund.
Neither Parent nor the Surviving Corporation shall be liable to any holder or former holder of
Company Common Stock or to any other Person with respect to any Cash Consideration delivered to any
public official pursuant to any applicable abandoned property law, escheat law or similar Legal
Requirement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.9 Closing of the Company&#146;s Transfer Books</B>. At the Effective Time: (a)&nbsp;all shares of Company
Common Stock outstanding immediately before the Effective Time shall automatically be canceled and
retired and shall cease to exist (in exchange for the right to receive the Per Share Merger
Consideration or the right to receive consideration pursuant to <U>Section&nbsp;1.5(d)</U>), and all
holders of Certificates or Book-Entry Shares that were outstanding immediately before the Effective
Time shall cease to have any rights as a Company Stockholder; and (b)&nbsp;the stock transfer books of
the Company shall be closed with respect to all shares of Company Common Stock outstanding
immediately before the Effective Time. No further transfer of any such shares of Company Common
Stock shall be made on such transfer books after the Effective Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.10 Lost Certificates</B>. If any Certificate shall have been lost, stolen, mutilated, or
destroyed, the Paying Agent will deliver in exchange for such lost, stolen or destroyed Certificate
the applicable portion of the Cash Consideration with respect to the shares of Company Common Stock
formerly represented thereby only after the person claiming such Certificate to be lost, stolen,
mutilated, or destroyed makes an affidavit to such effect and, if required by the Paying Agent,
delivers a bond (in customary amount) as indemnity against any claim that may be made against the
Paying Agent, Parent or the Surviving Corporation with respect to such Certificate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.11 Withholding Rights</B>. Each of the Surviving Corporation, Parent and the Paying Agent shall
be entitled to deduct and withhold from any consideration otherwise payable pursuant to this
Agreement to any holder of shares of Company Common Stock, Company Options or Company Warrants such
amounts as it is required to deduct and withhold with respect to the making of such payment under
the Code, the rules and regulations promulgated thereunder, any applicable non-United States Tax
Legal Requirements or any other applicable Legal Requirement. To the extent that amounts are so
withheld by the Surviving Corporation, Parent or the Paying Agent, as the case may be, such
withheld amounts shall be treated for all purposes of this Agreement as having been paid to the
holder of the shares of Company Common Stock, Company Options or Company Warrants in respect to
which such deduction and withholding was made by the Surviving Corporation, Parent or the Paying
Agent, as the case may be.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.12 Further Action</B>. If, at any time after the Effective Time, Parent or the Surviving
Corporation determines that any further action is necessary or desirable to carry out the purposes
of this Agreement or to vest the Surviving Corporation with full right, title and
possession of and to all rights and property of Merger Sub and the Company, the officers and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">directors of the Surviving Corporation and Parent shall be fully authorized (in the name of Merger
Sub, in the name of the Company and otherwise) to take such action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;2.</B> <FONT style="font-variant: SMALL-CAPS"><B>Representations and Warranties of the Company</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company represents and warrants to Parent and Merger Sub as follows, it being understood
that each representation and warranty contained in this <U>Section&nbsp;2</U> is subject to: (a)&nbsp;the
exceptions and disclosures set forth in the part or subpart of the Company Disclosure Schedule
corresponding to the particular Section or subsection in this <U>Section&nbsp;2</U> in which such
representation and warranty appears; (b)&nbsp;any exceptions or disclosures explicitly cross-referenced
in the part or subpart of the Company Disclosure Schedule corresponding to the particular Section
or subsection in this <U>Section&nbsp;2</U> in which such representation and warranty appears to
another part or subpart of the Company Disclosure Schedule; and (c)&nbsp;any exception or disclosure in
any other part or subpart of the Company Disclosure Schedule to the extent it is reasonably
apparent on the face or from the wording, of such exception or disclosure that such exception or
disclosure qualifies such other representation or warranty:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.1 Subsidiaries; Due Organization</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B><U>Schedule&nbsp;2.1(a)</U> of the Company Disclosure Schedule identifies each Subsidiary of
the Company and indicates its jurisdiction of organization. The Company is the owner of all of the
issued and outstanding shares of capital stock of each Subsidiary, free and clear of all
Encumbrances, and (in jurisdictions that recognize the following concepts) all such shares are duly
authorized, validly issued, fully paid and nonassessable and are not subject to any preemptive
right, right of first refusal or any similar right. Neither the Acquired Corporation nor any of
the Entities identified in <U>Schedule&nbsp;2.1(a)</U> of the Company Disclosure Schedule owns any
capital stock of, or any equity interest of any nature in, any other Entity, other than the
Entities identified in <U>Schedule&nbsp;2.1(a)</U> of the Company Disclosure Schedule. No Acquired
Corporation has agreed and no Acquired Corporation is obligated to make, nor or is it bound by any
Contract under which it may become obligated to make, any material future investment in or material
capital contribution to any other Entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Each of the Acquired Corporation (in jurisdictions that recognize the following concepts)
is a corporation duly organized, validly existing and in good standing under the laws of the state
of its incorporation and has all necessary corporate power and authority: (i)&nbsp;to conduct its
business in the manner in which its business is currently being conducted; (ii)&nbsp;to own and use its
assets in the manner in which its assets are currently owned and used; and (iii)&nbsp;to perform its
obligations under all Contracts by which it is bound, except, in each case, as would not reasonably
be expected to have a Company Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Each of the Acquired Corporations (in jurisdictions that recognize the following concepts)
is qualified to do business as a foreign corporation, and is in good standing, under the laws of
such jurisdictions where the nature of its business requires such qualification, except as would
not reasonably be expected to have a Company Material Adverse Effect.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.2 Capitalization, Etc</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The authorized capital stock of the Company consists of: (i)&nbsp;100,000,000 shares of Company
Common Stock, of which 15,371,121 shares were issued and outstanding as of the date of this
Agreement; (ii)&nbsp;one (1)&nbsp;share of Company Class&nbsp;B Common Stock, which is not issued or outstanding;
and (iii)&nbsp;10,000,000 shares of Company Preferred Stock, of which no shares are issued or
outstanding. As of the date of this Agreement, (1)&nbsp;1,384,576 shares of Company Common Stock are
subject to issuance pursuant to outstanding Company Options, (2)&nbsp;2,241,688 shares of Company Common
Stock are subject to issuance pursuant to outstanding Company Warrants, and (3)&nbsp;the Company does
not hold any shares of Company Common Stock in its treasury.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>All of the outstanding shares of Company Common Stock have been duly authorized and
validly issued, and are fully paid and nonassessable. None of the outstanding shares of Company
Common Stock is entitled or subject to, or was issued in violation of, any preemptive right, right
of participation, right of maintenance or any similar right. None of the outstanding shares of
Company Common Stock is subject to any right of first refusal in favor of the Company. To the
knowledge of the Company, there is no Company Contract currently in effect relating to the voting
of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or
granting any option or similar right with respect to), any shares of Company Common Stock. The
Company is not under any obligation, nor is it bound by any Contract to acquire, redeem or
otherwise acquire any outstanding shares of Company Common Stock or other securities, except for
the Company&#146;s right to acquire restricted shares of Company Common Stock held by a Company Employee
upon termination of such Company Employee&#146;s employment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Except for (i)&nbsp;the outstanding Company Options described in <U>Section&nbsp;2.2(a)(1)</U>
above and as set forth in <U>Schedule&nbsp;2.2(c)-1</U> of the Company Disclosure Schedule and (ii)&nbsp;the
outstanding Company Warrants described in <U>Section&nbsp;2.2(a)(2)</U> above and set forth in
<U>Schedule&nbsp;2.2(c)-2</U> of the Company Disclosure Schedule, as of the date of this Agreement,
there is no: (A)&nbsp;outstanding subscription, option, call, warrant or right (whether or not currently
exercisable) pursuant to a Contract to which the Company or any of its Subsidiaries is a party to
acquire any shares of the capital stock or other securities of the Company or any of its
Subsidiaries; (B)&nbsp;outstanding security, instrument or obligation that is or may become convertible
into or exchangeable for any shares of the capital stock or other securities of any of the Company
or any of its Subsidiaries; or (C)&nbsp;stockholder rights plan (or similar plan commonly referred to as
a &#147;poison pill&#148;) or Contract under which the Company or any of its Subsidiaries is or may become
obligated to sell or otherwise issue any shares of its capital stock or any other securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Each share of Company Common Stock outstanding immediately prior to the Effective Time
that is restricted and not fully vested under any applicable restricted stock agreement or other
Contract with the Company will become fully vested and unrestricted as of the Effective Time.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.3 ASX Filings; SEC Filings; Financial Statements</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>As of the time it was filed with the ASX or the SEC, as applicable: (i)&nbsp;the Company Public
Documents complied as to form in all material respects with the applicable requirements of the
Corporations Act, the ASX Listing Rules, Securities Act or the Exchange Act (as the case may be);
(ii)&nbsp;none of the Company ASX Documents omit material information required by the ASX Listing Rules
or materially contravenes Division 2 of Part&nbsp;7.10 of the Corporations Act; and (iii)&nbsp;none of the
Company SEC Documents contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; except to the extent
corrected: (A)&nbsp;in the case of Company Public Documents filed on or before the date of this
Agreement that were amended or superseded on or before the date of this Agreement, by the filing of
the applicable amending or superseding Company Public Document; and (B)&nbsp;in the case of Company
Public Documents filed after the date of this Agreement that are amended or superseded before the
Effective Time, by the filing of the applicable amending or superseding Company Public Document.
All statements, reports, schedules, forms and other documents required to have been filed by the
Company with or to or furnished to the SEC since September&nbsp;11, 2008 have been so filed or
furnished. Each of the principal executive officer and the principal financial officer of the
Company has made all certifications required by Rule&nbsp;13a-14 or Rule&nbsp;15d-14 under the Exchange Act
or under Sections&nbsp;302 and 906 of the Sarbanes-Oxley Act with respect to the Company SEC Documents
required to be filed before the date of this Agreement. As used in this Agreement, &#147;principal
executive officer&#148; and &#147;principal financial officer&#148; shall have the meanings given to such terms in
the Sarbanes-Oxley Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The financial statements (including any related notes) contained or incorporated by
reference in the Company Public Documents (i)&nbsp;were prepared in accordance with GAAP applied on a
consistent basis throughout the periods covered (except as may be indicated in the notes to such
financial statements or, in the case of unaudited financial statements, as permitted by Form 10-Q,
Form 8-K or any successor form under the Exchange Act, and except that the unaudited financial
statements may not contain footnotes and are subject to normal and recurring adjustments), and (ii)
fairly presented in all material respects in accordance with GAAP, the consolidated financial
position of the Company and its Subsidiaries as of the respective dates thereof, and the
consolidated results of operations and cash flows of the Company and its consolidated Subsidiaries
for the periods covered thereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>The Company has established and maintains a system of internal controls over financial
reporting sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in
accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as
necessary to permit preparation of financial statements in conformity with GAAP and to maintain
asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s
general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with
the existing assets at reasonable intervals and appropriate action is taken with respect to any
differences. To the knowledge of the Company, there were no material weaknesses, or series of
multiple significant deficiencies that are reasonably likely to collectively represent a material
weakness, in the design and operation of such internal controls. As used in this Agreement,
&#147;material weakness&#148; and &#147;significant
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">deficiencies&#148; shall have the meanings given to such term by the Public Company Accounting
Oversight Board.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>The Company has in place the &#147;disclosure controls and procedures&#148; (as defined in Rules
13a-15(e) and 15d-15(e) of the Exchange Act) required in order for the Chief Executive Officer and
Chief Financial Officer of the Company to engage in the review and evaluation process mandated by
the Exchange Act and the rules promulgated thereunder. The Company&#146;s disclosure controls and
procedures are reasonably designed to ensure that all information (both financial and
non-financial) required to be disclosed by the Company in the reports that it files or submits
under the Exchange Act is recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the SEC, and that all such information is accumulated and
communicated to the Company&#146;s management as appropriate to allow timely decisions regarding
required disclosure and to make the certifications of the Chief Executive Officer and Chief
Financial Officer of the Company required under the Exchange Act with respect to such reports.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>Since January&nbsp;1, 2006, neither the Company nor any of its directors, officers, employees
or, to the knowledge of the Company, auditors, accountants or representatives, has received or
otherwise had or obtained, actual knowledge of any complaint, allegation, assertion or claim,
whether written or oral, regarding the accounting or auditing practices, procedures, methodologies
or methods of the Company or its internal accounting controls, including any complaint, allegation,
assertion or claim that the Company has engaged in questionable accounting or auditing practices.
No attorney representing the Company, whether or not employed by the Company, has reported evidence
of a material violation of securities laws, breach of fiduciary duty or similar violation by the
Company or any of its directors, officers, employees or agents to the Company Board or any
committee thereof or to any director or executive officer of the Company. Since January&nbsp;1, 2006,
there have been no internal investigations regarding accounting treatment or revenue recognition,
in accordance with GAAP, discussed with, reviewed by or initiated at the direction of the Company&#146;s
chief executive officer, chief financial officer, chief accounting officer or principal legal
counsel or the Company Board or any committee thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>To the knowledge of the Acquired Corporation, no employee of any Acquired Corporations has
provided or is providing information to any law enforcement agency regarding the commission or
possible commission of any crime or the violation or possible violation of any Legal Requirement.
Neither the Acquired Corporations nor any officer or employee or, to the knowledge of the Acquired
Corporations, any contractor, subcontractor or agent of any Acquired Corporation, has discharged,
demoted, suspended, threatened, harassed or in any other manner discriminated against any employee
of any Acquired Corporation in the terms and conditions of employment because of any act of such
employee described in 18 U.S.C. &#167; 1514A(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g) </B>No Acquired Corporation has, and none of the Acquired Corporations is reasonably expected
to have any accrued, contingent or other liabilities of any nature, either matured or unmatured,
that are, individually or in the aggregate, material to the Acquired Corporations, except for: (i)
liabilities identified as such, or specifically reserved against, in the consolidated balance sheet
of the Company as of March&nbsp;31, 2009 (the &#147;<B><I>Company</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>Unaudited Balance Sheet Date</I></B>&#148;) contained in the Company Public Documents (the &#147;<B><I>Company
Unaudited Balance Sheet</I></B>&#148;); (ii)&nbsp;current liabilities that have been incurred by the Acquired
Corporations since the date of the Company Unaudited Balance Sheet in the ordinary course of
business and consistent with past practices; (iii)&nbsp;liabilities for performance of obligations of
the Acquired Corporations pursuant to the express terms of Company Contracts; (iv)&nbsp;liabilities
incurred by the Acquired Corporation in connection with the Contemplated Transactions; (v)
liabilities of a type which would not be required to be included in a balance sheet (or the notes
thereto) prepared in accordance with GAAP that are not, individually or in the aggregate, material
to the Acquired Corporation; and (vi)&nbsp;liabilities described in <U>Schedule&nbsp;2.3(e)</U> of the
Company Disclosure Schedule.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.4 Absence of Changes</B>. Since the date of the Company Unaudited Balance Sheet:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>there has not been any Company Material Adverse Effect;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>the Company has not: (i)&nbsp;declared, accrued, set aside or paid any dividend or made any
other distribution in respect of any shares of capital stock, other than distributions of Company
Common Stock issued upon the exercise of Company Options; or (ii)&nbsp;acquired, redeemed or otherwise
reacquired any shares of its capital stock or other securities, other than pursuant to the
Company&#146;s right to acquire restricted shares of Company Common Stock held by a Company Employee
upon termination of such Company Employee&#146;s employment;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>there has been no amendment to the certificate of incorporation or bylaws of any Acquired
Corporations;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>neither the Company nor any of its Subsidiaries has lent money to any Person (other than
advances to employees in the ordinary course of business);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>the Company has not materially changed any of its methods of accounting or accounting
practices, except as required by concurrent changes in GAAP or SEC rules and regulations;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>no Acquired Corporation has made any material Tax election;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;</B>neither the Company nor any of its Subsidiaries has commenced or settled any material
Legal Proceeding; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(h)&nbsp;</B>neither the Company nor, if applicable, any of its Subsidiaries, has agreed or committed
to take any of the actions referred to in clauses &#147;(b)&#148; through &#147;(g)&#148; above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.5 Title to Assets</B>. The Company and each of its Subsidiaries owns, and has good and valid
title to, all material assets purported to be owned by them, including all material assets
reflected on the Company Unaudited Balance Sheet (except for assets sold or otherwise disposed of
since the date of the Company Unaudited Balance Sheet in the ordinary course of business). To the
knowledge of the Acquired Corporations, all of said assets are owned by the Company or one of its
Subsidiaries free and clear of any Encumbrances, except for liens
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">described in <U>Schedule&nbsp;2.5</U> of the Company Disclosure Schedule. The Company or one
of its Subsidiaries is the lessee of, and holds valid leasehold interests in, all material assets
purported to have been leased by them, including all material assets reflected as leased on the
Company Unaudited Balance Sheet (it being understood that the representations and warranties
contained in this <U>Section&nbsp;2.5</U> do not apply to ownership of, or Encumbrances with respect
to, Intellectual Property and Intellectual Property Rights, which matters are addressed solely in
the representations and warranties set forth in <U>Section&nbsp;2.7</U>).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.6 Real Property; Leasehold</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The Company and its Subsidiaries do not own any real property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B><U>Schedule&nbsp;2.6(b)</U> of the Company Disclosure Schedule sets forth an accurate and
complete list of each lease: (i)&nbsp;pursuant to which any real property is being leased to the Company
or any of its Subsidiaries; and (ii)&nbsp;having aggregate lease payments in excess of $50,000 over the
12-month period commencing on the date of this Agreement. (All real property leased to the Company
or any of its Subsidiaries is referred to as the &#147;<B><I>Leased Real Property</I></B>&#148;). There is no Legal
Proceeding pending, and to the knowledge of the Acquired Corporation no Legal Proceeding has been
threatened, that challenges or adversely affects, or would challenge or adversely affect, the
continuation of the present use or operations by the Acquired Corporations of any Leased Real
Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B><U>Schedule&nbsp;2.6(c)</U> of the Company Disclosure Schedule contains an accurate and
complete list of all subleases, occupancy agreements and other Company Contracts granting to any
Person (other than the Company or any of its Subsidiaries) a right of use or occupancy of any of
the Leased Real Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>All material items of equipment and other material tangible assets owned by or leased to
the Acquired Corporations are adequate for the uses to which they are being put, are in good and
safe condition and repair (ordinary wear and tear excepted) and are adequate for the conduct of the
businesses of the Acquired Corporations in the manner in which such businesses are currently being
conducted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.7 Intellectual Property</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B><U>Schedule&nbsp;2.7(a)</U> of the Company Disclosure Schedule sets forth a complete and
accurate list of all Company Registered IP. All Company Registered IP is subsisting (or in the
case of applications, applied for) and to the knowledge of the Company, valid and enforceable. All
filings, payments and other actions required to be made or taken by the Company or any of its
Subsidiaries before the date of this Agreement to maintain each item of Company Registered IP have
been made and taken.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Each item of Company Owned IP is owned exclusively by the Company or its Subsidiaries,
free and clear of any Encumbrances other than Permitted Encumbrances. To the knowledge of the
Company and its Subsidiaries, the Company Owned IP and the Company In-Licensed IP constitute all of
the Intellectual Property Rights necessary for the conduct of the business of the Company and its
Subsidiaries as it is currently conducted or currently planned to be conducted by the Company and
its Subsidiaries. For purposes of <U>Section </U>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>2.7(b)</U> and <U>Section&nbsp;2.7(f)</U>, the phrase &#147;currently planned to be conducted by
the Company and its Subsidiaries&#148; means the development, manufacturing, marketing, sale, offer for
sale, exportation, distribution and/or use of any of the following: (i)&nbsp;PEP005 (ingenol mebutate)
Gel for the treatment of actinic keratosis; (ii)&nbsp;PEP005 (ingenol mebutate) Gel for the treatment of
non-melanoma skin cancers; and (iii)&nbsp;PEP005 (ingenol mebutate) Gel for the treatment of cutaneous
warts. There is no Legal Proceeding, including reexamination, opposition, cancellation or similar
active proceeding, pending or, to the knowledge of the Company and its Subsidiaries, threatened
with respect to any Company Owned IP.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Neither the execution, delivery or performance of this Agreement nor the consummation of
any of the Contemplated Transactions would reasonably be expected to, with or without notice or the
lapse of time, result in or give any other Person the right or option to cause, create, impose or
declare: (i)&nbsp;a loss of, or Encumbrance on, any Company Owned IP or any Company In-Licensed IP; or
(ii)&nbsp;the grant, assignment or transfer to any other Person of any license or other right or
interest under, to or in any Company Owned IP or Company In-Licensed IP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>The Company and its Subsidiaries have taken commercially reasonable steps (including
measures to protect secrecy and confidentiality) to protect the Company&#146;s and its Subsidiaries&#146;
rights in trade secrets of the Company and its Subsidiaries. Without limiting the generality of
the foregoing, each former and current employee or director of the Acquired Corporation and each
former and current third-party consultant and contractor of the Acquired Corporations having access
to confidential information or trade secrets of the Acquired Corporations has executed a valid and
enforceable written agreement with the Company or any of its Subsidiaries, as applicable,
containing obligations to protect, preserve, and maintain the confidentiality of all trade secrets
of the Company and its Subsidiaries (such contract terms, a &#147;<B><I>Nondisclosure Agreement</I></B>&#148;). To the
knowledge of the Company, no current or former employee, director, consultant or contractor is in
breach of any Nondisclosure Agreement or IP Assignment Agreement (as defined below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>To the knowledge of the Company, no Person is infringing, misappropriating or otherwise
violating, any Company Owned IP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>To the knowledge of the Company, the conduct of the business of the Company and its
Subsidiaries as it is currently conducted or currently planned to be conducted by the Company and
its Subsidiaries (as defined in <U>Section&nbsp;2.7(b)</U>) does not infringe or misappropriate any
Intellectual Property Right of any other Person. To the knowledge of the Company as of the date of
this Agreement, the development, manufacturing, marketing, sale, offer for sale, exportation,
distribution and/or use of any Company Product does not infringe or misappropriate any Intellectual
Property Right of any other Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;</B>Neither the Company nor any of its Subsidiaries has been sued in any Legal Proceeding (or
received any written notice or, to the knowledge of the Company, threat) which involves a claim of
infringement or misappropriation of any Intellectual Property Right of any other Person or which
contests the validity, ownership or right of the Company or any of its Subsidiaries to exercise any
right in Company Owned IP.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(h)&nbsp;</B>No Company Owned IP has been developed or otherwise obtained, in whole or part, through
the use of funding, facilities, or other resources of any Governmental Body or institution of
higher learning or under any Contract with any Governmental Body or institution of higher learning.
To the knowledge of the Company, none of the activities of the employees of the Company or any of
its Subsidiaries violates any Contract, or fiduciary duty that any such employee has with a former
employer, and no such former employer has asserted in writing to the Company or any of its
Subsidiaries any such violation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>The Company and each of its Subsidiaries has secured from each of their current and former
consultants and employees (each a &#147;<B><I>Contributor</I></B>&#148;) who independently or jointly is or was involved
in, or contributes or contributed to the conception, reduction to practice, creation or development
of any, Company Owned IP, ownership of all such Contributor&#146;s Intellectual Property Rights in such
involvement or contribution that the Company or such Subsidiary does not already own by operation
of law and such Contributor has not retained any rights or licenses with respect thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.8 Contracts</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B><U>Schedule&nbsp;2.8</U> of the Company Disclosure Schedule identifies each Company Contract
that constitutes a Company Significant Contract as of the date of this Agreement. For purposes of
this Agreement, each of the following shall be deemed to constitute a &#147;<B><I>Company Significant
Contract</I></B>&#148;:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>any Contract constituting a Company Employee Agreement: (A)&nbsp;pursuant to which the Company
or any of its Subsidiaries is or may become obligated to make any severance, termination or similar
payment in excess of $10,000 to any Company Employee (except as may be required by applicable Legal
Requirements); (B)&nbsp;pursuant to which the Company or any of its Subsidiaries is or may become
obligated to make any bonus or similar payments (other than payments constituting base salary or
commissions paid in the ordinary course of business) in excess of $10,000 to any individual Company
Employee; (C)&nbsp;pursuant to which any Acquired Corporation is or may become obligated to extend the
post-termination exercise period of any Company Option beyond the period set forth in the
applicable Company Option Plan; or (D)&nbsp;pursuant to which any of the Acquired Corporation is or may
become obligated to provide any benefit to a Company Employee upon termination (with or without
cause) of such Company Employee&#146;s employment or other relationship (other than statutory benefits
required by applicable law);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>any Contract pursuant to which the Company or any of its Subsidiaries licenses from any
Person (other than the Company and its Subsidiaries) any Intellectual Property Rights (other than
software license agreements for any third-party software that is generally available to the public
at a cost of less than $50,000 per year entered into by the Company or any of its Subsidiaries in
the ordinary course of business);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>any Contract pursuant to which the Company or any of its Subsidiaries licenses to any
Person (other than the Company and its Subsidiaries) any Company Owned IP;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>any Contract with any distributor or other reseller or sales representative;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(v)&nbsp;</B>any Contract that provides for: (A)&nbsp;reimbursement of any Company Employee for, or
advancement to any Company Employee of, legal fees or other expenses associated with any Legal
Proceeding or the defense thereof; or (B)&nbsp;indemnification of any Company Employee;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vi)&nbsp;</B>any Contract imposing any restriction on the right or ability of the Company or any of
its Subsidiaries: (A)&nbsp;to compete with any other Person; (B)&nbsp;to acquire any product or other asset
or any services from any other Person; (C)&nbsp;to develop, sell, manufacture, license, market,
assemble, supply, distribute, offer, support or service any product or any technology or other
asset to or for any other Person; (D)&nbsp;to perform services for any other Person; (E)&nbsp;to transact
business with any other Person; or (F)&nbsp;to operate at any location in the world;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vii)&nbsp;</B>any Contract evidencing indebtedness in excess of $50,000;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(viii)&nbsp;</B>any Contract relating to the lease or sublease of Leased Real Property;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ix)&nbsp;</B>any labor or collective bargaining Contract;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(x)&nbsp;</B>any Contract for pre-clinical, testing, clinical or marketing trials relating to the
Company Products and Contracts with physicians, hospitals, clinics or other healthcare providers;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xi)&nbsp;</B>any joint venture or partnership Contract or Contract requiring the sharing of profits;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xii)&nbsp;</B>any Contract pursuant to which any third party is entitled to market any of the Company
Products;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xiii)&nbsp;</B>any Contract under which another party processes, produces or manufactures, or will
process, produce or manufacture, any of the Company Products and any Contract with suppliers of any
component or active ingredient of the Company Products;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xiv)&nbsp;</B>any Contract pursuant to which the Company or any Subsidiary has acquired a business or
entity, or assets of a business or entity, whether by way of merger, consolidation, purchase of
stock, purchase of assets, license or otherwise, or any contract pursuant to which it has any
material ownership interest in any other Person;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xv)&nbsp;</B>any other Contract that by its terms involves the payment or delivery of cash or other
consideration in an amount or having a value, individually or in the aggregate, in excess of
$100,000 in any individual fiscal year which is not terminable without material penalty by the
Company on less than 90&nbsp;days&#146; notice;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xvi)&nbsp;</B>any Contract for Company In-Licensed IP with respect to a Company Product containing an
express requirement for diligence by any Acquired Corporation in the development, marketing,
manufacture or sale of such Company Product;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xvii)&nbsp;</B>any Contract incorporating or relating to any guaranty or performance of obligation of
another party, any product or service warranty or any sharing of liabilities, except for Contracts
which do not differ materially from the standard forms made available by the Company to Parent;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xviii)&nbsp;</B>any Contract relating to any currency hedging, swap or other financial derivative,
material credit facility, outstanding letter of credit or bank guarantee;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xix)&nbsp;</B>any Contract (other than Contracts evidencing Company Options or Company Warrants): (A)
relating to the acquisition, issuance, voting, registration, sale or transfer of any securities;
(B)&nbsp;providing any Person with any preemptive right, right of participation, right of maintenance or
similar right with respect to any securities; or (C)&nbsp;providing to or imposing upon any of the
Acquired Corporations any right of first refusal with respect to, or right or obligation to
repurchase or redeem, any securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xx)&nbsp;</B>any other Contract, if a breach or termination of such Contract would reasonably be
expected to have or result in a Company Material Adverse Effect; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xxi)&nbsp;</B>any other Contract not listed in <U>Sections&nbsp;2.8(a)(i)-(xxi)</U> that would be a
&#147;material contract&#148; under Rule&nbsp;601 of Regulation&nbsp;S-K of the SEC.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company has delivered or made available to Parent an accurate and complete copy of each Company
Contract that constitutes a Company Significant Contract.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Each Company Significant Contract, including any Subsidiary Contract (as defined in the
Company Disclosure Schedule), is valid and in full force and effect and is enforceable in
accordance with its terms, subject to: (i)&nbsp;laws of general application relating to bankruptcy,
insolvency and the relief of debtors; and (ii)&nbsp;rules of law governing specific performance,
injunctive relief and other equitable remedies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>(i)&nbsp;Neither the Company nor any of its Subsidiaries is in breach or any default under any
Company Contract; (ii)&nbsp;to the knowledge of the Company, no other Person is in breach or any default
under, any Company Contract; and (iii)&nbsp;to the knowledge of the Company, no event has occurred and
is continuing, and no circumstance or condition exists, that (with or without notice or lapse of
time) would reasonably be expected to: (A)&nbsp;result in a violation or breach of any of the provisions
of any Company Contract; (B)&nbsp;give any Person the right to declare a default under any Company
Contract; (C)&nbsp;give any Person the right to receive or require a rebate, chargeback, penalty or
change in delivery schedule under any Company Contract; (D)&nbsp;give any Person the right to accelerate
the maturity or performance of any Company Contract; or (E)&nbsp;give any Person the right to cancel,
terminate or modify any Company Contract.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.9 Compliance with Legal Requirements</B>. Each of the Company and its Subsidiaries is and has
been since January&nbsp;1, 2006, in compliance in all material respects with all applicable Legal
Requirements. Since January&nbsp;1, 2006, neither the Company nor any of its Subsidiaries have received
any notice from any Governmental Body or other Person regarding any actual or possible violation in
any material respect of, or failure to comply in any material respect with, any Legal Requirement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.10 Certain Business Practices</B>. Neither the Company, any of its Subsidiaries, nor, to the
knowledge of the Company, any Company Employee with respect to any matter relating to the Company
and its Subsidiaries, has: (a)&nbsp;used any funds for unlawful contributions, gifts, entertainment or
other unlawful expenses relating to political activity; or (b)&nbsp;made any unlawful payment to foreign
or domestic government officials or employees or to foreign or domestic political parties or
campaigns or violated any provision of the Foreign Corrupt Practices Act of 1977, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.11 Governmental Authorizations</B>. The Company and its Subsidiaries hold all material
Governmental Authorizations necessary to enable the Company and its Subsidiaries to conduct their
respective businesses in the manner in which such businesses are currently being conducted. All
such Governmental Authorizations are valid and in full force and effect. Each Acquired Corporation
is, and at all times has been, in compliance in all material respects with the terms and
requirements of such Governmental Authorizations. Since January&nbsp;1, 2006, neither the Company nor
any of its Subsidiaries has received any written notice from any Governmental Body regarding: (i)
any actual or possible violation of or failure to comply with any term or requirement of any
material Governmental Authorization; or (ii)&nbsp;any actual or possible revocation, withdrawal,
suspension, cancellation, termination or modification of any material Governmental Authorization.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.12 Tax Matters</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Each of the material Tax Returns required to be filed by or on behalf of the Company and
its Subsidiaries with any Governmental Body with respect to any Taxable period ending on or before
the Closing Date: (i)&nbsp;has been or will be filed on or before the applicable due date (including any
extensions of such due date); (ii)&nbsp;has been or will be accurate and complete in all material
respects; and (iii)&nbsp;has been, or will be when filed, prepared in all material respects in
substantial compliance with all applicable Legal Requirements. All amounts shown on the material
Tax Returns to be due on or before the Closing Date have been or will be paid on or before the
Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The Company and its Subsidiaries have withheld and paid all material Taxes required to
have been withheld and paid in connection with any amounts paid to any employee, independent
contractor, creditor, stockholder, or other third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>The Company Unaudited Balance Sheet reflects all liabilities for unpaid material Taxes of
the Company and/or any Subsidiary for periods (or portions of periods) through the Company
Unaudited Balance Sheet Date. Neither the Company nor any Subsidiary has any liability for unpaid
material Taxes accruing after the Company Unaudited Balance Sheet
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Date except for Taxes arising in the ordinary course of business subsequent to the Company
Unaudited Balance Sheet Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>To the knowledge of the Company, no material Tax Return is currently subject to an audit
by any Governmental Body. No extension or waiver of the limitation period applicable to any of the
material Tax Returns has been granted by the Company or any of its Subsidiaries, and no such
extension or waiver has been requested from the Company or any of its Subsidiaries. Neither the
Company nor any of its Subsidiaries has granted to any Person any power of attorney that is
currently in force with respect to any Tax matter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>No Legal Proceeding is pending with respect to the Company or any of its Subsidiaries in
respect of any material Tax. There are no unsatisfied liabilities for material Taxes with respect
to any notice of deficiency or similar document received by the Company or any of its Subsidiaries
with respect to any material Tax (other than liabilities for Taxes asserted under any such notice
of deficiency or similar document which are being contested in good faith by the Company or one of
its Subsidiaries). There are no Encumbrances for material Taxes upon any of the assets of the
Company and its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>There are no Contracts relating to allocating or sharing of Taxes to which the Company or
any of its Subsidiaries is a party, other than Contracts among one or more of the Company and any
of its Subsidiaries. Neither the Company nor any of its Subsidiaries is liable for the Taxes of
any other Person (other than the Company and its Subsidiaries), nor is it currently under any
contractual obligation to indemnify any Person (other than the Company and its Subsidiaries) with
respect to any amounts of such Person&#146;s Taxes (except for customary agreements to indemnify lenders
or security holders in respect of Taxes) nor are they a party to any Contract providing for
payments by the Company or any of its Subsidiaries with respect to any amount of Taxes of any other
Person (other than the Company and its Subsidiaries).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;</B>The Company has not constituted either a &#147;distributing corporation&#148; or a &#147;controlled
corporation&#148; that was purported or intended to be governed by Section&nbsp;355 of the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(h)&nbsp;</B>Neither the Company nor any of its Subsidiaries has been a member of an affiliated group
of corporations within the meaning of Section&nbsp;1504 of the Code or within the meaning of any similar
Legal Requirement to which the Company or any of its Subsidiaries may be subject, other than the
affiliated group of which the Company is the common parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Neither the Company nor any of its Subsidiaries has entered into any &#147;listed transaction&#148;
within the meaning of Treasury Regulation&nbsp;Section&nbsp;1.6011-4(b)(2).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(j)&nbsp;</B>The Company has made available to Parent or its legal or accounting representatives copies
of all foreign, federal and state income Tax Returns and all other material Tax Returns filed by or
on behalf of the Company and its Subsidiaries and examination reports and statements of
deficiencies assessed against or agreed to by the Company or any Subsidiary for all periods
including and after the period ended December&nbsp;31, 2004.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.13 Employee and Labor Matters; Benefit Plans</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>To the knowledge of the Company, no Company Employee is a party to or is bound by any
noncompetition agreement that may have a material effect on the business or operations of the
Company and its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Neither the Company nor any of its Subsidiaries is a party to any collective bargaining
agreement or other Contract with a labor organization representing any Company Employee, and there
are no labor organizations representing, purporting to represent or, to the knowledge of the
Company, seeking to represent any Company Employee. There is not now pending, and, to the
knowledge of the Company, no Person has threatened in writing to commence, any strike, slowdown,
work stoppage, lockout, job action, picketing, labor dispute, question regarding representation or
union organizing activity or any similar activity. There is no material claim or grievance pending
or, to the knowledge of the Company, threatened in writing relating to any employment Contract,
wages and hours, plant closing notification, labor dispute, immigration or discrimination matters
involving any Company Employee, including charges of unfair labor practices or harassment
complaints.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>None of the current independent contractors of the Company or any of its Subsidiaries
could reasonably be reclassified as an employee, except as would not reasonably be expected to
result in a material liability to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B><U>Schedule&nbsp;2.13(d)</U> of the Company Disclosure Schedule contains an accurate and
complete list of each Company Employee Plan and each Company Employee Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>The Company has delivered or made available to Parent accurate and complete copies, as of
the date of this Agreement, of copies of each Company Employee Plan, including all amendments
thereto and all related trust documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>Each Company Employee Plan has been established and maintained in all material respects in
accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;</B>Except as expressly required or provided by this Agreement, neither the execution of this
Agreement nor the consummation of the Contemplated Transactions will or would reasonably be
expected to (either alone or upon the occurrence of termination of employment) constitute an event
under any Company Employee Plan or Company Employee Agreement that will or may result (either alone
or in connection with any other circumstance or event) in any material payment (whether of
severance pay or otherwise), acceleration, forgiveness of indebtedness, vesting, distribution,
increase in benefits or obligation to fund benefits with respect to any Company Employee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(h)&nbsp;</B>&nbsp;There is no agreement, plan, arrangement or other Contract covering any Company Employee,
that, considered individually or considered collectively with any other such Contracts or payments,
will, or would reasonably be expected to, be characterized as a &#147;parachute payment&#148; within the
meaning of Section&nbsp;280G(b)(2) of the Code or give rise directly or indirectly to the payment of any
amount that would not be deductible pursuant to Section&nbsp;162(m) of the Code (or any comparable
provision under state or foreign Tax laws).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Neither the Company nor any of its Subsidiaries is a party to or has any obligation under any
Contract to compensate any Person for excise taxes payable pursuant to Section&nbsp;4999 of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Each Company Employee Plan that is a &#147;nonqualified deferred compensation plan&#148; (as defined
under Section&nbsp;409A(d)(1) of the Code) has been operated in good faith compliance with Section&nbsp;409A
of the Code, as permitted thereunder or under any other IRS guidance regarding good faith
compliance with Section&nbsp;409A of the Code from the period beginning January&nbsp;1, 2005 through December
31, 2008, and is in compliance with the Treasury Regulations promulgated under Section&nbsp;409A of the
Code from January&nbsp;1, 2009 through the date hereof. Any amount paid or payable pursuant to each
Company Employee Plan subject to Section&nbsp;409A of the Code is not includible in the gross income of
a service provider (within the meaning of Section&nbsp;409A) until received by the service provider and
is not subject to interest or the additional tax imposed by Section&nbsp;409A of the Code, and there are
no agreements in place that would entitle a participant in any such plan to reimbursement for any
such additional Tax.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.14 Transactions with Affiliates</B>. Except as set forth in the Company SEC Documents filed
before the date of this Agreement, since January&nbsp;1, 2006, no event has occurred that would be
required to be reported by the Company pursuant to Item&nbsp;404 of Regulation&nbsp;S-K promulgated by the
SEC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.15 Legal Proceedings; Orders</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>(i)&nbsp;There is no pending Legal Proceeding and (ii)&nbsp;to the knowledge of the Company, no
Governmental Body or other Person has threatened to commence any Legal Proceeding, to which the
Company or any of its Subsidiaries is a party, or is threatened to become a party, that, in each
case, (A)&nbsp;would reasonably be expected to result in a material liability to any Acquired
Corporation or that if adversely determined, would reasonably be expected to have or result in a
Company Material Adverse Effect; or (B)&nbsp;that challenges, or that may have the effect of preventing,
delaying, making illegal or otherwise interfering with, the Merger. To the Company&#146;s knowledge, no
event has occurred, and no claim, dispute or other condition or circumstance exists, that would
reasonably be expected to give rise to, or serve as a basis for, the commencement of any such Legal
Proceedings described in clauses &#147;(A)&#148; and &#147;(B)&#148; above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>There is no pending Legal Proceeding that (A)&nbsp;based on the merits of such Legal
Proceeding, has a reasonably significant likelihood of being determined in a manner adverse to the
Company or any of its Subsidiaries, and (B)&nbsp;if adversely determined, would reasonably be expected
to result in a material and adverse effect on the Company&#146;s ability to develop or market or
otherwise recognize revenues from the marketing of PEP005 (ingenol mebutate). There is no Order
materially and adversely affecting the Company&#146;s ability to develop or market or otherwise
recognize revenues from the marketing of PEP005 (ingenol mebutate) to which the Company or any of
its Subsidiaries, or any of their respective material assets, is subject.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>There is no material Order to which the Company or any of its Subsidiaries, or any of
their respective material assets, is subject.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.16 Regulatory Matters</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>To the Company&#146;s knowledge, each of its clinical trials or pre-clinical studies were (or,
if still pending, are being), conducted in accordance all material respects with applicable
protocols, procedures and controls and all applicable Legal Requirements administered by the FDA
and comparable foreign Governmental Bodies (including the TGA). No investigational new drug
application filed by or on behalf of the Company with the FDA has been terminated or suspended by
the FDA, and neither the FDA nor any applicable foreign Governmental Body has commenced, or, to the
knowledge of the Company, threatened to initiate, any action to place a clinical hold order on, or
otherwise terminate or suspend, any ongoing clinical trial conducted by or on behalf of the Company
or in which the Company has participated with respect to any Company Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>All material reports, documents, claims and notices required to be filed, maintained, or
furnished to the FDA and TGA by the Company or any of its Subsidiaries have been so filed,
maintained or furnished. All such reports, documents, claims, and notices were complete and
correct in all material respects on the date filed (or were corrected in or supplemented by a
subsequent filing) such that no material liability exists with respect to such filing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Neither the Company nor any of its Subsidiaries have received any written notices from the
FDA or TGA alleging or asserting material noncompliance with any applicable Legal Requirements or
Governmental Authorizations issued by the FDA or TGA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>To the knowledge of the Company, the manufacture of Company Products is being conducted in
material compliance with &#147;good manufacturing practices&#148; as defined by the FDA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>Neither the Company nor its Subsidiaries has been convicted of any crime or engaged in any
conduct which could result in debarment or disqualification by the FDA or any drug regulatory
agency, and there are no proceedings pending or, to the knowledge of the Company, threatened that
reasonably might be expected to result in criminal liability or debarment or disqualification by
the FDA or any drug regulatory agency.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.17 Environmental Compliance</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Without limiting the generality of <U>Section&nbsp;2.17(b)</U>, the Company and its
Subsidiaries possesses, and is in material compliance with, all permits, licenses and Governmental
Authorizations and has filed all material notices that are required under applicable Environmental
Laws (as defined below), including all such permits, licenses and other Governmental Authorization
required to lawfully use and occupy the premises occupied by the Acquired Corporations (including
the Leased Real Property). Each of the permits, licenses and Governmental Authorizations referred
to&nbsp;in the preceding sentence has been at all relevant times effective and the Acquired Corporation
have not received any notice of, and are not aware of, any circumstances which might lead to any
proposed revocation, cancellation, withdrawal,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">amendment, variation, surrender or refusal of any such permits, licenses and Governmental
Authorizations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The Company and its Subsidiaries is and has been in compliance in all material respects
with all, and has not been and is not in material violation of or subject to any material liability
under any, applicable Environmental Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>No the Acquired Corporations is the subject of any pending or threatened Legal Proceedings
or received any notice involving a demand for damages or other liability for a breach or violation
of any Environmental Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>No Acquired Corporations has received any notice of, or is aware of, any circumstances
which might lead to a liability in connection with any Environmental Law with respect to any
Acquired Corporation, the premises occupied by any Acquired Corporations (including the Leased Real
Property) or the current or past use or occupation on or about such premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>The conduct of the business by the Acquired Corporations does not constitute a nuisance,
nor has any claim been made in respect of the use or operation of the premises occupied by the
Acquired Corporations (including the Leased Real Property) by any adjoining landowner or other
party or government agency.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For purposes of this <U>Section&nbsp;2.17</U>: (i) &#147;<B><I>Environmental Law</I></B>&#148; means any federal, state, local
or foreign Legal Requirement relating to land use, development and building occupation, pollution
or protection of human health or the environment (including ambient air, surface water, ground
water, land surface or subsurface strata), including any Legal Requirement relating to emissions,
discharges, releases or threatened releases of Materials of Environmental Concern, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Materials of Environmental Concern; (ii) &#147;<B><I>Materials of Environmental Concern</I></B>&#148;
include chemicals, pollutants, contaminants, wastes, toxic substances, petroleum and petroleum
products and any other substance that is that is a danger to health, reproduction or the
environment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.18 Insurance</B>. Neither the Company nor any of its Subsidiaries has made any pending material
claim against any of its material insurance policies as to which coverage has been denied by the
provider of such policies. Each of the material insurance policies and all material self insurance
programs and arrangements relating to the business, assets and operations of the Acquired
Corporations is in full force and effect. None of the Acquired Corporations has received any
written notice or, to the knowledge of the Acquired Corporations, overt communication regarding any
actual or possible: (a)&nbsp;cancellation or invalidation of any such insurance policy; or (b)&nbsp;written
notice of refusal of any coverage or rejection of any material claim under any such insurance
policy. With respect to each Legal Proceeding that has been filed against any Acquired Corporation,
the Company has provided written notice of such Legal Proceeding to the appropriate insurance
carrier(s), if any, and, no such carrier has issued a denial of coverage or a reservation of rights
with respect to any such Legal Proceeding, or informed any of the Acquired Corporations of its
intent to do so.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.19 Authority</B>. The Company has all requisite right, power and authority to enter into and to
perform and, subject to obtaining the Required Company Stockholder Vote, consummate its obligations
under this Agreement. The Company Board (at a meeting duly called and held) has unanimously: (a)
determined that the Merger is advisable and fair to, and in the best interests of, the Company and
the Company Stockholders; (b)&nbsp;authorized and approved the execution, delivery and performance of
this Agreement by the Company and approved the Merger; (c)&nbsp;recommended the adoption of this
Agreement by the holders of Company Common Stock and directed that this Agreement and the Merger be
submitted for adoption by the Company Stockholders at the Company Stockholders&#146; Meeting; and (d)&nbsp;to
the extent necessary, adopted a resolution having the effect of causing the Company not to be
subject to any state takeover law or similar Legal Requirement that might otherwise apply to the
Merger or any of the other transactions contemplated by this Agreement. Assuming due execution and
delivery of this Agreement by Parent and Merger Sub, this Agreement will constitute a valid and
binding obligation of the Company, enforceable against it in accordance with its terms, subject to
the effect, if any, of (i)&nbsp;applicable bankruptcy and other similar laws affecting the rights of
creditors generally, and (ii)&nbsp;rules of law governing specific performance, injunctive relief, and
other equitable remedies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.20 Non-Contravention; Consents</B>. Assuming compliance with the applicable provisions of the
Exchange Act, the Corporations Act, the DGCL, the HSR Act and any foreign Antitrust Laws (as
defined below), and the applicable requirements of the ASX Listing Rules, except as set forth in
<U>Schedule&nbsp;2.20</U> of the Company Disclosure Schedule, neither (1)&nbsp;the execution and delivery of
this Agreement by the Company, nor (2)&nbsp;the consummation of the Merger or any of the other
Contemplated Transactions, will or would reasonably be expected to, directly or indirectly (with or
without notice or lapse of time):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>contravene, conflict with or result in a violation of&nbsp;any of the provisions of the
certificate of incorporation or bylaws (or similar documents) of the Company or any of its
Subsidiaries;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>contravene, conflict with or result in a violation of, any Legal Requirement or any Order
to which the Company, any of its Subsidiaries, or any of their respective material assets are
subject;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>contravene, conflict with or result in a violation of any of the terms or requirements of
any Governmental Authorization that is held by the Company or any of its Subsidiaries or that
otherwise relates to the business of the Company and its Subsidiaries;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>contravene, conflict with or result in a material violation or material breach of, or
result in a material default under, any provision of any Company Contract, or give any Person the
right to: (i)&nbsp;declare a material default or exercise any material remedy under any such Company
Contract; (ii)&nbsp;receive or obtain a material rebate, chargeback, penalty or change in delivery
schedule under any such Company Contract; (iii)&nbsp;accelerate the maturity or performance of any such
Company Contract; or (iv)&nbsp;cancel, terminate or materially modify any right, benefit, obligation or
other term of such Company Contract; or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>result in the imposition or creation of any Encumbrance upon or with respect to any asset
owned or used by the Company or any of its Subsidiaries;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company is not, and will not be, required to make any filing with or give any notice to, or to
obtain any Consent from, any Person in connection with: (i)&nbsp;the execution, delivery or performance
of this Agreement; or (ii)&nbsp;the consummation of the Merger or any of the other Contemplated
Transactions, except in each case as may be required by the applicable provisions of the Exchange
Act, the Corporations Act, the DGCL, the HSR Act and any foreign Antitrust Laws, and the applicable
requirements of the ASX Listing Rules.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.21 Information Supplied</B>. The preliminary and definitive proxy statements to be filed by the
Company with the SEC and the ASX and sent to the Company Stockholders in connection with the
Company Stockholders&#146; Meeting and any amendments or supplements thereto (collectively, the &#147;<B><I>Proxy
Statement</I></B>&#148;), shall not, on each relevant filing date, on the date of mailing to the Company
Stockholders and at the time of the Company Stockholders&#146; Meeting, (a)&nbsp;contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which they are made, not
false or misleading; or omit to state any material fact necessary to correct any statement in any
earlier communication with respect to the solicitation of proxies for the Company Stockholders&#146;
Meeting which has become false or misleading or (b)&nbsp;contravene the Corporations Act, including
Division 2 of Part&nbsp;7.10, or any ASIC class orders, ASIC relief or &#147;no action&#148; letter issued by
ASIC. The Proxy Statement will comply as to form in all material respects with the provisions of
the Exchange Act and the rules and regulations thereunder. If at any time before the Effective
Time the Company discovers any event relating to the Company or any of its Affiliates which is
required to be set forth in a supplement to the Proxy Statement, the Company shall inform Parent
reasonably promptly. Notwithstanding the foregoing, the Company makes no representation or
warranty with respect to any information supplied by Parent or Merger Sub that is contained in the
Proxy Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.22 Fairness Opinion</B>. Before the execution of this Agreement, the Company received opinions
from Goldman, Sachs &#038; Co., financial advisor to the Company, and Leerink Swann LLC to the effect
that, as of the respective dates of such respective opinions and based upon and subject to the
matters set forth in their respective opinions, the Per Share Merger Consideration to be paid to
the holders of shares of Company Common Stock (other than any shares of Company Common Stock held
by Parent, Merger Sub or any other wholly owned Subsidiary of Parent) is fair, from a financial
point of view, to such holders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.23 Financial Advisor</B>. Except for Goldman, Sachs &#038; Co., and Leerink Swann LLC (with respect
to its opinion), no broker, finder or investment banker is entitled to any brokerage, finder&#146;s or
other fee or commission in connection with the Merger or any of the other Contemplated Transactions
based upon arrangements made by or on behalf of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.24 Delaware Section&nbsp;203</B>. The Company Board has taken all actions necessary to provide that
the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL are not,
and will not be, applicable to the execution, delivery or performance of this Agreement or the
Voting Agreements or to the consummation of the Merger or any of the other Contemplated
Transactions. Prior to the execution of the Voting Agreements,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the board of directors of the Company approved the Voting Agreements and the matters
contemplated thereby for purposes of Section&nbsp;203 of the DGCL. To the knowledge of the Company,
except for Section&nbsp;203 of the DGCL, no state takeover statute or similar Legal Requirement applies
or purports to apply to the Merger, this Agreement or any of the Contemplated Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.25 Full Disclosure</B>. This Agreement (including the Company Disclosure Schedule) does not,
and the certificate referred to in <U>Section&nbsp;6.5</U> will not, (i)&nbsp;contain any representation or
warranty with respect to any of the Acquired Corporations or the business, financial condition,
capitalization or results of operations of any of the Acquired Corporations that is false or
misleading with respect to any material fact; or (ii)&nbsp;to the knowledge of the Company, omit to
state any material fact with respect to any of the Acquired Corporations or the business, financial
condition, capitalization or results of operations of any of the Acquired Corporations necessary in
order to make the representations and, warranties contained herein and to be contained therein (in
the light of the circumstances under which such representations and warranties were or will be made
or provided) not false or misleading. The information and data made available by the Company to
Parent with respect to PEP005 (ingenol mebutate) does not contain any false or misleading
information with respect to any material fact with respect to PEP005 (ingenol mebutate); or, to the
knowledge of the Company, omit to state any material fact necessary to make the information
provided not false or misleading with respect to PEP005 (ingenol mebutate).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.26 No Other Representations</B>. The Company acknowledges that the representations and
warranties of Parent and Merger Sub set forth in this Agreement and in any document or instrument
delivered by or on behalf of Parent or Merger Sub pursuant hereto or in connection with the Merger
or the other Contemplated Transactions constitute the sole and exclusive representations and
warranties of Parent and Merger Sub to the Company in connection with the Merger and the other
Contemplated Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;3.</B> <FONT style="font-variant: SMALL-CAPS"><B>Representations and Warranties of Parent and Merger Sub </B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent and Merger Sub represent and warrant to the Company as follows, it being understood
that each representation and warranty contained in this <U>Section&nbsp;3</U> is subject to: (a)&nbsp;the
exceptions and disclosures set forth in the part or subpart of the Parent Disclosure Schedule
corresponding to the particular Section or subsection in this <U>Section&nbsp;3</U> in which such
representation and warranty appears; (b)&nbsp;any exceptions or disclosures explicitly cross-referenced
in the part or subpart of the Company Disclosure Schedule corresponding to the particular Section
or subsection in this <U>Section&nbsp;3</U> in which such representation and warranty appears to
another part or subpart of the Parent Disclosure Schedule; and (c)&nbsp;any exception or disclosure in
any other part or subpart of the Parent Disclosure Schedule to the extent it is reasonably apparent
on the face or from the wording, of such exception or disclosure that such exception or disclosure
qualifies such other representation or warranty:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.1 Due Organization</B>. Each of Parent and Merger Sub is a corporation duly organized, validly
existing and in good standing under the laws of their respective jurisdictions of incorporation and
have all necessary corporate power and authority: (a)&nbsp;to conduct their businesses in the manner in
which their businesses are currently being conducted; (b)&nbsp;to own and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">use their assets in the manner in which their assets are currently owned and used; and (c)&nbsp;to
perform their obligations under all Contracts by which they are bound, except, in each case, as
would not reasonably be expected to have a Parent Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.2 Legal Proceedings</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>(i)&nbsp;There is no pending Legal Proceeding; and (ii)&nbsp;to the knowledge of Parent, no
Governmental Body or other Person has threatened in writing to commence any Legal Proceeding; to
which Parent is a party or is threatened to become a party, that (A)&nbsp;questions or challenges (1)
the validity of this Agreement or (2)&nbsp;any action required to be taken by Parent hereunder or (B)
would reasonably be expected to have a Parent Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>As of the date of this Agreement, there is no Order to which Parent, or any of its
material assets, is subject, except as would not reasonably be expected to have a Parent Material
Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.3 Authority</B>. Each of Parent and Merger Sub has the corporate right, power and authority to
enter into and to perform and consummate their respective obligations under this Agreement. The
board of directors of Parent (at a meeting duly called and held or acting by unanimous written
consent) has authorized and approved the execution, delivery and performance of this Agreement by
Parent. The board of directors of Merger Sub (at a meeting duly called and held or acting by
unanimous written consent) has: (a)&nbsp;determined that the Merger is advisable and fair to, and in the
best interests of, Merger Sub and its sole stockholder; (b)&nbsp;authorized and approved the execution,
delivery and performance of this Agreement by Merger Sub and approved the Merger; and (c)
recommended the adoption of this Agreement by the sole stockholder of Merger Sub and directed that
this Agreement and the Merger be submitted for consideration by the sole stockholder of Merger Sub.
Parent, as the sole stockholder of Merger Sub, has adopted this Agreement. No other action on the
part of Parent&#146;s or Merger Sub&#146;s board of directors or stockholders is required to approve this
Agreement or perform and consummate the Merger. Assuming due execution and delivery of this
Agreement by the Company, this Agreement will constitute a valid and binding obligation of Parent
and Merger Sub, enforceable against them in accordance with its terms, subject to the effect, if
any, of (i)&nbsp;applicable bankruptcy and other similar laws affecting the rights of creditors
generally, and (ii)&nbsp;rules of law governing specific performance, injunctive relief, and other
equitable remedies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.4 Non-Contravention; Consents</B>. Assuming compliance with the applicable provisions of the
Exchange Act, the Corporations Act, the HSR Act and any foreign Antitrust Laws, and the applicable
requirements of the ASX Listing Rules, neither (1)&nbsp;the execution and delivery of this Agreement by
Parent and Merger Sub, nor (2)&nbsp;the consummation of the Merger or any of the other Contemplated
Transactions, will or would reasonably be expected to, directly or indirectly (with or without
notice or lapse of time):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>contravene, conflict with or result in a violation of&nbsp;any of the provisions of the
certificate of incorporation or bylaws of Parent or Merger Sub;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>contravene, conflict with or result in a violation of any Legal Requirement or any Order
to which Parent or Merger Sub, or any of their material assets, is subject; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>contravene, conflict with or result in a violation or breach of, or result in a default
under, any provision of any material Contract of Parent,
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">except, in the case of clauses &#147;(b)&#148; and &#147;(c)&#148; of this sentence, as would not reasonably be
expected to have a Parent Material Adverse Effect. Neither Parent nor Merger Sub is or will be
required to make any filing with or give any notice to, or to obtain any Consent from, any Person
in connection with: (i)&nbsp;the execution, delivery or performance of this Agreement; or (ii)&nbsp;the
consummation of the Merger or any of the other Contemplated Transactions, except in each case: (A)
as may be required by the applicable provisions of the Exchange Act, the Corporations Act, the HSR
Act and any foreign Antitrust Laws, and the applicable requirements of the ASX Listing Rules; or
(B)&nbsp;the failure of which to make such filing, give such notice, or obtain such Consent, would not
reasonably be expected to have a Parent Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.5 Information Supplied</B>. The information supplied by Parent for inclusion in the Proxy
Statement shall not, on each relevant filing date, on the date of mailing to the Company
Stockholders and at the time of the Company Stockholders&#146; Meeting, (a)&nbsp;contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which they are made, not
misleading, or omit to state any material fact necessary in order to make the statements therein,
in the light of the circumstances under which they are made, not misleading, or (b)&nbsp;contravene the
Corporations Act, including Division 2 of Part&nbsp;7.10, or any ASIC class order, ASIC relief or &#147;no
action&#148; letter issued by ASIC. If at any time before the Effective Time, any event relating to
Parent or any of its Affiliates should be discovered by Parent which is required to be set forth in
a supplement to the Proxy Statement, Parent shall promptly inform the Company. Notwithstanding the
foregoing, Parent makes no representation or warranty with respect to any information supplied by
the Company or any other information which is contained in the Proxy Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.6 Financial Advisor</B>. Except for Morgan Stanley, no broker, finder or investment banker is
entitled to any brokerage, finder&#146;s or other fee or commission in connection with the Merger or any
of the other Contemplated Transactions based upon arrangements made by or on behalf of Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.7 Ownership of Company Common Stock</B>. As of the date of this Agreement, neither Parent, nor
any Subsidiary of Parent, nor any Affiliate or associate of Parent, owns more than 15% of the
outstanding voting stock of the Company, as determined in accordance with the provisions of Section
203 of the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.8 No Prior Merger Sub Operations</B>. Merger Sub was formed solely for the purpose of effecting
the Merger and has not engaged in any business activities or conducted any operations other than in
connection with the Contemplated Transactions.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.9 Sufficient Funds</B>. Parent has, and will have available to it upon the consummation of the
Merger, without any need for outside financing, sufficient funds to consummate the Contemplated
Transactions, including payment in full of all cash amounts contemplated by <U>Section&nbsp;1</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.10 No Other Representations</B>. Parent and Merger Sub acknowledge that the representations and
warranties of the Company set forth in this Agreement and in any document or instrument delivered
by or on behalf of the Company pursuant hereto or in connection with the Merger or the other
Contemplated Transactions constitute the sole and exclusive representations and warranties of the
Company to Parent and Merger Sub in connection with the Merger and the other Contemplated
Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;4.</B> <FONT style="font-variant: SMALL-CAPS"><B>Certain Covenants of the Parties </B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.1 Access and Investigation</B>. During the period commencing on the date of this Agreement and
ending as of the earlier of the Effective Time or the earlier termination of this Agreement
pursuant to <U>Section&nbsp;8</U> (the &#147;<B><I>Pre-Closing Period</I></B>&#148;), the Company shall and shall cause the
respective Representatives of the Acquired Corporations to: (a)&nbsp;provide Parent and Parent&#146;s
Representatives with reasonable access during normal business hours, on reasonable prior notice, to
the personnel and assets of the Acquired Corporations and to all existing books, records, Tax
Returns, work papers and other documents and information relating to the Acquired Corporations; and
(b)&nbsp;provide or make available to Parent and Parent&#146;s Representatives, at Parent&#146;s expense, such
copies of the existing books, records, Tax Returns, and other documents and information relating to
the Acquired Corporations and with such additional financial, operating and other data and
information regarding the Acquired Corporations as Parent may reasonably request. Without limiting
the generality of the foregoing, during the Pre-Closing Period and subject to applicable Antitrust
Laws, the Company and Parent shall promptly provide the other party with copies of any notice,
report or other document filed with or sent to any Governmental Body on behalf of the Company,
Parent or Merger Sub, as applicable, in connection with the Merger or any of the other Contemplated
Transactions The foregoing shall not require the Company to permit any inspection, or to disclose
any information, that could reasonably be expected to result in (i)&nbsp;the disclosure of any trade
secrets of third parties or the violation of any obligations of the Company with respect to
confidentiality or non-disclosure if the Company shall have used reasonable efforts to obtain the
consent of such third party to such inspection or disclosure, (ii)&nbsp;the waiver of any applicable
attorney-client privilege or (iii)&nbsp;the violation of any applicable Legal Requirement;. Without
limiting the generality of the foregoing, during the Pre-Closing Period and subject to applicable
Antitrust Laws, the Company shall promptly provide Parent with:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>all material regularly recurring operating and financial reports prepared by the Acquired
Corporations for the Company&#146;s senior management, including copies of the unaudited monthly
consolidated balance sheets of the Acquired Corporations and the related unaudited monthly
consolidated statements of operations, statements of stockholders&#146; equity and statements of cash
flows;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>any material notice, report or other document received by any of the Acquired Corporations
from any Governmental Body;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>any written communication alleging a material breach of any Company Contract that comes to
the attention of any officer or senior manager of the Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>any written materials or communications sent by or on behalf of the Company to its
stockholders generally; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>any notice, report or other document filed with or sent to any Governmental Body on behalf
of any of the Acquired Corporations in connection with the Merger or any of the other Contemplated
Transactions.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If the access to certain information to be granted to Parent pursuant to this <U>Section&nbsp;4.1</U>
would reasonably be expected to result in a violation of applicable Legal Requirements or would
otherwise be unreasonably disruptive to the operations of the Company, the Company and Parent shall
cooperate in good faith to develop an alternative to furnishing such information to Parent and its
Representatives to address such matters that is reasonably acceptable to Parent and the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.2 Operations Before Closing</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>During the Pre-Closing Period: (i)&nbsp;the Company shall conduct and cause each of the other
Acquired Corporations to conduct its business and operations in the ordinary course and in
compliance with all applicable Legal Requirements and the requirements of all Company Contracts
that constitute Company Significant Contracts (including renewal of the Acquired Corporations&#146;
Flammable and Combustible Liquid Storage License); (ii)&nbsp;the Company shall use its commercially
reasonable efforts to ensure that each of the Acquired Corporations preserves intact its current
business organization, keeps available the services of its current officers and other employees and
maintains its relations and goodwill with all suppliers, customers, landlords, creditors,
licensors, licensees, distributors, resellers, employees and other Persons having business
relationships with the respective Acquired Corporations; (iii)&nbsp;the Company shall use commercially
reasonable efforts to keep in full force all insurance policies referred to in <U>Section&nbsp;2.18</U>
(other than any such policies that are immediately replaced with substantially similar policies);
and (iv)&nbsp;the Company shall promptly notify Parent of (A)&nbsp;any written notice or other overt
communication of which the Company has knowledge from any Person alleging that the Consent of such
Person is or may be required in connection with any of the Contemplated Transactions, and (B)&nbsp;any
Legal Proceeding commenced, or, to the knowledge of the Company, threatened against, relating to,
involving or otherwise affecting any of the Acquired Corporations that relates to the consummation
of the Merger or any of the other Contemplated Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Except as set forth in <U>Schedule&nbsp;4.2(b)</U> of the Company Disclosure Schedule, during
the Pre-Closing Period, the Company shall not and the Company shall ensure that each of the other
Acquired Corporations does not (without the prior written consent of Parent):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>declare, accrue, set aside or pay any dividend or make any other distribution in respect
of any shares of capital stock, or acquire, redeem or otherwise reacquire any shares of capital
stock or other securities, other than pursuant to the Company&#146;s
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">right to acquire restricted shares of Company Common Stock held by a Company Employee upon
termination of such Company Employee&#146;s employment;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>sell, issue, grant or authorize the sale, issuance or grant of: (A)&nbsp;any capital stock or
other security; (B)&nbsp;any option, call, warrant or right to acquire any capital stock or other
security; or (C)&nbsp;any instrument convertible into or exchangeable for any capital stock or other
security (except that the Company may issue shares of Company Common Stock upon the valid exercise
of Company Options or Company Warrants outstanding as of the date of this Agreement);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>amend or waive any of its rights under, or accelerate the vesting under, any provision
of any of the Company Option Plan or any provision of any Contract evidencing any outstanding
Company Option or any restricted stock purchase agreement, or otherwise modify any of the terms of
any outstanding option, restricted stock units, warrant or other security or any related Contract,
other than any acceleration of vesting that occurs in accordance with the terms of a Company
Contract in effect as of the date of this Agreement or the terms of this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>amend or, except as contemplated pursuant to <U>Section&nbsp;5.3(a)</U> of this Agreement or
any Company Contract in existence as of the date of this Agreement, accelerate the vesting under,
any provision of any of the Company Option Plan or any provision of any agreement evidencing any
outstanding stock option or any restricted stock purchase agreement, or otherwise modify any of the
terms of any outstanding option, warrant or other security, except as required by applicable Legal
Requirements;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(v)&nbsp;</B>amend or permit the adoption of any amendment to its certificate of incorporation or
bylaws;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vi)&nbsp;</B>acquire any equity interest or other interest in any other Entity; or effect or become a
party to any merger, consolidation, share exchange, business combination, amalgamation,
recapitalization, reclassification of shares, stock split, reverse stock split, division or
subdivision of shares, consolidation of shares or similar transaction;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vii)&nbsp;</B>enter into any Contract that would impose any restriction on the right or ability of the
Company or any of its Subsidiaries: (A)&nbsp;to compete with any other Person; (B)&nbsp;to acquire any
product or other asset or any services from any other Person; (C)&nbsp;to develop, sell, manufacture,
license, market, assemble, supply, distribute, offer, support or service any product or any
technology or other asset to or for any other Person; (D)&nbsp;to perform services for any other Person;
(E)&nbsp;to transact business with any other Person; or (F)&nbsp;to operate at any location in the world;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(viii)&nbsp;</B>make any capital expenditure (except that the Company may make any capital expenditures
in amounts consistent with the operating budget attached as Exhibit&nbsp;A to that certain Loan
Agreement, dated of even date herewith, by and between the Company and Parent);
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ix)&nbsp;</B>other than in the ordinary course of business consistent with past practices, amend,
terminate (other than expiration in accordance with its terms) or waive any material right or
remedy under, any Company Significant Contract;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(x)&nbsp;</B>acquire, lease or license any right or other asset from any other Person or sell or
otherwise dispose of, or lease or license, any right or other asset to any other Person (except in
each case for assets: (A)&nbsp;acquired, leased, licensed or disposed of by the Company in the ordinary
course of business; or (B)&nbsp;that are not material to the business of the Company);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xi)&nbsp;</B>make any pledge of any of its material assets or permit any of its material assets to
become subject to any Encumbrances;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xii)&nbsp;</B>(A)&nbsp;enter into or become bound by, or permit any of the assets owned or used by it to
become bound by, any Company Significant Contract or (B)&nbsp;amend or terminate, or waive any material
right or remedy under, any Company Significant Contract;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xiii)&nbsp;</B>enter into, renew or become bound by, or permit any of the assets owned or used by it
to become bound by, any Contract the effect of which would be to grant to any Person following the
Merger any actual or potential right or license to any Intellectual Property Right owned as of the
date of this Agreement by any Acquired Corporation or Parent;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xiv)&nbsp;</B>other than in the ordinary course of business consistent with past practices or as
required by GAAP, write off as uncollectible, or establish any extraordinary reserve with respect
to, any receivable or other indebtedness;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xv)&nbsp;</B>lend money to any Person (other than advances to Company Employees in the ordinary course
of business), or, except in the ordinary course of business, incur or guarantee any indebtedness;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xvi)&nbsp;</B>establish, adopt, enter into or amend any Company Employee Plan or Company Employee
Agreement, pay any bonus or make any profit-sharing or similar payment to, or increase the amount
of the wages, salary, commissions, fringe benefits or other compensation (including equity-based
compensation, whether payable in stock, cash or other property) or remuneration payable to, any
Company Employees (except that the Company: (A)&nbsp;may provide routine salary increases to Company
Employees in the ordinary course of business and in connection with the Company&#146;s customary
employee review process; (B)&nbsp;may enter into Company Employee Agreements with newly-hired Company
Employees; (C)&nbsp;may amend the Company Employee Plans to the extent required by applicable Legal
Requirements; and (D)&nbsp;may make customary bonus payments in accordance with bonus plans existing on
the date of this Agreement);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xvii)&nbsp;</B>hire any employee with an annual base salary in excess of $80,000;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xviii)&nbsp;</B>other than in the ordinary course of business or as required by concurrent changes in
GAAP or SEC rules and regulations, change any of its methods of accounting or accounting practices
in any material respect;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xix)&nbsp;</B>make or change any material Tax election, amend or file a claim for refund with respect
to any Tax Return, compromise or settle any Legal Proceeding with respect to any Tax or Tax-related
matter, enter into or obtain any Tax ruling or take any action that would reasonably be expected to
have a material and adverse impact on the Tax liability of any Acquired Corporation, except as
required under applicable Legal Requirements;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xx)&nbsp;</B>form any Subsidiary or acquire any equity interest or other interest in any other Entity;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xxi)&nbsp;</B>commence (other than planning) any new clinical trial involving any Company Product,
except for: (A)&nbsp;such clinical trials that are made pursuant to the Acquired Corporations&#146; plan as
shared with Parent prior to the date of this Agreement; and (B)&nbsp;as requested in writing by the FDA;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xxii)&nbsp;</B>assign or grant an exclusive license of any material Intellectual Property Right
relating to technology necessary for the manufacture, use, sale, offer for sale or importation of
Company Products;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xxiii)&nbsp;</B>commence any Legal Proceeding, except: (A)&nbsp;with respect to routine matters in the
ordinary course of business; (B)&nbsp;in such cases where the Company reasonably determines in good
faith that the failure to commence suit would result in a material impairment of a valuable aspect
of its business; or (C)&nbsp;in connection with a breach of this Agreement or related to the
Contemplated Transactions;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xxiv)&nbsp;</B>settle any claim or Legal Proceeding; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xxv)&nbsp;</B>agree or commit to take any of the actions described in clauses &#147;(i)&#148; through &#147;(xxiv)&#148;
of this <U>Section&nbsp;4.2(b)</U>.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If the Company desires to take an action that requires the prior written consent of Parent pursuant
to this <U>Section&nbsp;4.2(b)</U>, the Company shall deliver to Parent a written request for such
written consent. Parent shall use commercially reasonable efforts to approve or deny the Company&#146;s
request as soon as reasonably practicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Parent, as the sole stockholder of Merger Sub, shall cause Merger Sub to perform its
obligations under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>During the Pre-Closing Period, the Company shall promptly notify Parent in writing after
learning of: (i)&nbsp;the discovery by the Company of any event, condition, fact or circumstance that
occurred or existed on or prior to the date of this Agreement and that caused or constitutes a
material breach of any representation or warranty made by the Company in this Agreement; (ii)&nbsp;any
event, condition, fact or circumstance that occurs, arises or exists after the date of this
Agreement and that would cause or constitute a material breach of any representation or warranty
made by the Company in this Agreement if: (A)&nbsp;such representation or warranty had
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">been made as of the time of the occurrence, existence or discovery of such event, condition,
fact or circumstance; or (B)&nbsp;such event, condition, fact or circumstance had occurred, arisen or
existed on or prior to the date of this Agreement; (iii)&nbsp;any material breach of any covenant or
obligation of the Company; and (iv)&nbsp;any event, condition, fact or circumstance that would make the
timely satisfaction of any of the conditions set forth in <U>Section&nbsp;6</U> or <U>Section&nbsp;7</U>
impossible or unlikely or that has had or would reasonably be expected to have a Company Material
Adverse Effect. Without limiting the generality of the foregoing, the Company shall promptly
advise Parent in writing of any Legal Proceeding or material claim threatened, commenced or
asserted against or with respect to any of the Acquired Corporations. No notification given to
Parent pursuant to this <U>Section&nbsp;4.2(d)</U> or any information or knowledge obtained pursuant to
<U>Section&nbsp;4.1</U> shall limit or otherwise affect any of the representations, warranties,
covenants or obligations of the Company contained in this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>During the Pre-Closing Period, Parent shall promptly notify the Company in writing of: (i)
the discovery by Parent of any event, condition, fact or circumstance that occurred or existed on
or prior to the date of this Agreement and that caused or constitutes a material breach of any
representation or warranty made by Parent in this Agreement; (ii)&nbsp;any event, condition, fact or
circumstance that occurs, arises or exists after the date of this Agreement and that would cause or
constitute a material breach of any representation or warranty made by Parent in this Agreement if:
(A)&nbsp;such representation or warranty had been made as of the time of the occurrence, existence or
discovery of such event, condition, fact or circumstance; or (B)&nbsp;such event, condition, fact or
circumstance had occurred, arisen or existed on or prior to the date of this Agreement; (iii)&nbsp;any
material breach of any covenant or obligation of Parent; and (iv)&nbsp;any event, condition, fact or
circumstance that would make the timely satisfaction of any of the conditions set forth in
<U>Section&nbsp;6</U> or <U>Section&nbsp;7</U> impossible or unlikely or that has had or would reasonably
be expected to have a Parent Material Adverse Effect. No notification given to the Company pursuant
to this <U>Section&nbsp;4.2(e)</U> shall limit or otherwise affect any of Parent&#146;s representations,
warranties, covenants or obligations contained in this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>During the Pre-Closing Period, the Company shall (and shall cause each of the other
Acquired Corporations to): (i)&nbsp;use commercially reasonable efforts consistent with past practices
to prepare and prosecute the approval by the FDA and other Governmental Bodies of all pending
applications for any of the Company Products and use commercially reasonable efforts to develop the
Company Products; (ii)&nbsp;use commercially reasonable efforts to promote, market and commercialize the
Company Products in the jurisdictions in which they have obtained regulatory approval; (iii)&nbsp;use
commercially reasonable efforts to obtain and maintain on a commercially reasonable basis such
quantities of finished Company Products and related raw materials and components as the Acquired
Corporations reasonably expect to be required for ongoing and anticipated clinical and commercial
use; and (iv)&nbsp;to the extent requested by Parent, cause its officers to report to Parent concerning
the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;</B>During the Pre-Closing Period, the Company shall use commercially reasonable efforts to
monitor the performance and fulfillment of diligence obligations of all licensees, sublicensees and
contractors of the Acquired Corporations and their respective affiliates, any clinical research
organization and all clinical trial sites for any Company Product.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(h)&nbsp;</B>During the Pre-Closing Period, the Company shall (i)&nbsp;consult with Parent in connection
with any proposed meeting with the FDA or any other Governmental Body relating to any Company
Product and promptly provide Parent with a summary report of any such meeting that occurs, (ii)
provide Parent with a reasonable opportunity to review any material filing made by or on behalf of
any of the Acquired Corporations, and any material correspondence or other material communication
submitted or otherwise transmitted to the FDA or any other Governmental Body by or on behalf of any
of the Acquired Corporations, in each case relating to any Company Product (it being understood
that this subsection &#147;(h)&#148; does not confer upon Parent the right to determine the content of such
communication), <I>provided</I>, <I>that, </I>the Company shall not be required to delay any filings with, or the
submission of any correspondence to and communications with the FDA in connection with any review
by Parent as long as the subject correspondence or communication was provided promptly to Parent;
and (iii)&nbsp;notify Parent of all proposed meetings with the FDA, or any other Governmental Body
(whether scientific or others) as soon as possible and allow Parent and its Representative to
attend and observe such meetings to the extent reasonably feasible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.3 No Solicitation</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>During the Pre-Closing Period, the Company shall not, directly or indirectly, and shall
ensure that the other Acquired Corporations and their respective Representatives do not directly or
indirectly:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>solicit, initiate or knowingly encourage, induce or facilitate the making, submission or
announcement of any Acquisition Inquiry or Acquisition Proposal;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>furnish or make available any non-public information regarding the Company to any Person
in connection with or in response to an Acquisition Inquiry or Acquisition Proposal;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>engage in discussions or negotiations with any Person with respect to any Acquisition
Inquiry or Acquisition Proposal;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>approve, endorse or recommend any Acquisition Proposal; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(v)&nbsp;</B>enter into any letter of intent or similar document or any Contract contemplating or
otherwise relating to any Acquisition Transaction;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>provided, however, </I>that prior to the Company Stockholders&#146; Meeting, this <U>Section&nbsp;4.3(a)</U>
shall not prohibit the Company from furnishing or making available non-public information regarding
the Company to, entering into discussions and negotiations with, or amending, waiving or releasing
restrictions contained in any standstill or similar agreement applicable to, any Person in response
to an unsolicited, bona fide, written Acquisition Proposal (that has not been withdrawn) that
constitutes, or would reasonably be expected to lead to, a Superior Offer if: (A)&nbsp;the Company Board
concludes in good faith, after having consulted with outside legal counsel and its financial
advisor, that the failure to take such action would be reasonably likely to constitute a breach of
its fiduciary obligations to the Company Stockholders under applicable Legal Requirements; (B)&nbsp;at
least two (2)&nbsp;Business Days prior to furnishing or making available any
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">such non-public information to, or entering into discussions or negotiations with, or taking such
action regarding, such Person, the Company gives Parent written notice of the identity of such
Person and of the Company&#146;s intention to furnish or make available non-public information to, or
enter into discussions or negotiations with, such Person, and the Company receives from such Person
an executed confidentiality agreement the terms of which are at least as restrictive as the terms
contained in the Confidentiality Agreement; (C)&nbsp;at least two (2)&nbsp;Business Days prior to furnishing
or making available any such non-public information to such Person, the Company furnishes or makes
available such non-public information to Parent (to the extent the Company has not previously
furnished or made available such non-public information to Parent); and (D)&nbsp;such Acquisition
Proposal did not result directly or indirectly from a breach by any Acquired Corporation or any of
its Representatives of the provisions set forth in, this <U>Section&nbsp;4.3</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The Company shall promptly (and in no event later than 48 hours after receipt of any
Acquisition Inquiry or Acquisition Proposal) advise Parent of any Acquisition Inquiry or
Acquisition Proposal (including the identity of the Person making or submitting such Acquisition
Inquiry or Acquisition Proposal, and the material terms thereof) that is made or submitted by any
Person during the Pre-Closing Period. The Company shall keep Parent informed in all material
respects with respect to: (i)&nbsp;the status of any such Acquisition Inquiry or Acquisition Proposal;
and (ii)&nbsp;the status and material terms of any modification or proposed modification thereto. The
Company agrees that it shall not enter any confidentiality agreement with any Person subsequent to
the date of this Agreement that prohibits the Company from providing such information to Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>The Company shall immediately cease and cause to be terminated any discussions ongoing as
of the date of this Agreement with any Person that relate to any Acquisition Proposal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>The Company agrees not to release or permit the release of any Person from, or to waive or
permit the waiver of any provision of, any confidentiality, non-solicitation, no hire, &#147;standstill&#148;
or similar agreement to which any of the Acquired Corporations is a party or under which any of the
Acquired Corporations has any rights, and will use its reasonable best efforts to cause each such
agreement to be enforced at the request of Parent. The Company also shall promptly request each
Person that has executed a confidentiality or similar agreement in connection with its
consideration of a possible Acquisition Transaction or a possible equity investment in any Acquired
Corporation to return to the Acquired Corporations, or, alternatively, to destroy and certify to
the Company the destruction of, all confidential information heretofore furnished to such Person by
or on behalf of any of the Acquired Corporations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>Without limiting the generality of the foregoing, the Company acknowledges and agrees that
any action inconsistent with any of the provisions set forth in the preceding provisions of this
<U>Section&nbsp;4.3</U> by any Representative of any of the Acquired Corporations, whether or not such
Representative is purporting to act on behalf of any of the Acquired Corporations, shall be deemed
to constitute a breach of this <U>Section&nbsp;4.3</U> by the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;5.</B> <FONT style="font-variant: SMALL-CAPS"><B>Additional Covenants of the Parties </B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.1 Company Proxy Statement</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The Company shall (i)&nbsp;prepare and cause to be filed with the SEC preliminary proxy
materials to obtain the Required Company Stockholder Vote promptly after the date of this Agreement
and (ii)&nbsp;cause a copy of those preliminary proxy materials to be filed with the ASX. Promptly
following the later of (i)&nbsp;receipt and resolution of SEC comments thereon or (ii)&nbsp;the expiration of
the 10-day waiting period provided in Rule&nbsp;14a-6(a) promulgated under the Exchange Act, the Company
shall file definitive proxy materials with the SEC and the ASX, and cause the Proxy Statement to be
mailed to the Company Stockholders. The Company will cause all documents that it is responsible for
filing with the SEC or other regulatory authorities in connection with the Merger (or as required
or appropriate to facilitate the Merger) to (x)&nbsp;comply as to form with all applicable SEC
requirements, and (y)&nbsp;otherwise comply with all applicable Legal Requirements. Prior to filing the
preliminary proxy materials, definitive proxy materials or any other filing with the SEC, the ASX
or any other Governmental Body, the Company shall provide Parent with reasonable opportunity to
review and comment on each such filing in advance, and the Company shall consider in good faith the
comments proposed by or on behalf of Parent with respect thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The Company will notify Parent promptly of the receipt of any comments from the SEC or its
staff (or of notice of the SEC&#146;s intent to review the Proxy Statement) and of any request by the
SEC or its staff or any other government officials for amendments or supplements to the Proxy
Statement or any other filing or for additional/supplemental information, and will promptly supply
Parent with copies of all correspondence between the Company or any of its Representatives, on the
one hand, and the SEC, or its staff or any other government officials, on the other hand, with
respect to the Proxy Statement or other filing. The Company shall provide Parent with reasonable
opportunity to review and comment on any written response in advance, and the Company shall
consider in good faith and implement where necessary or appropriate the comments proposed by or on
behalf of Parent with respect thereto. Without limiting the foregoing, the Company shall respond
promptly to any comments of the SEC or its staff or any other government officials and use
commercially reasonable efforts to have the Proxy Statement cleared by the SEC or any other
government officials as promptly as practicable after it has been filed. The Company shall advise
Parent promptly after it receives notice that the Proxy Statement has been cleared by the SEC or
any other government officials. Whenever any event occurs that is required to be set forth in an
amendment or supplement to the Proxy Statement or any other filing, the Company shall promptly
inform Parent of such occurrence, provide Parent with reasonable opportunity to review and comment
on any such amendment or supplement in advance, and shall cooperate in filing with the SEC or its
staff or any other government officials, and/or, to the extent required, mailing to the Company
Stockholders, such amendment or supplement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.2 Company Stockholders&#146; Meeting</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The Company shall take all action necessary under all applicable Legal Requirements to
call, give notice of and hold a meeting of the Company Stockholders to vote on the adoption of this
Agreement (the &#147;<B><I>Company Stockholders&#146; Meeting</I></B>&#148;). The Company Stockholders&#146; Meeting shall be held
(on a date selected by the Company, subject to the approval of Parent), as promptly as practicable
and in accordance with applicable Legal Requirements, after the Proxy Statement has been cleared by
the SEC or any other government officials. The Company shall ensure that all proxies solicited in
connection with the Company Stockholders&#146; Meeting are solicited in compliance with all applicable
Legal Requirements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Subject to <U>Section&nbsp;5.2(c)</U>: (i)&nbsp;the Proxy Statement shall include a statement to
the effect that the Company Board (i)&nbsp;has unanimously determined that the Merger and this Agreement
are advisable and (ii)&nbsp;unanimously recommends that the Company Stockholders vote to adopt this
Agreement at the Company Stockholders&#146; Meeting (the unanimous determination that the Merger and
this Agreement are advisable and the unanimous recommendation of the Company Board that the Company
Stockholders vote to adopt this Agreement being collectively referred to as the &#147;<B><I>Company Board
Recommendation</I></B>&#148;); and (ii)&nbsp;the Company Board Recommendation shall not be withdrawn or modified in a
manner adverse to Parent, and no resolution by the Company Board or any committee thereof to
withdraw the Company Board Recommendation or to modify the Company Board Recommendation in a manner
adverse to Parent shall be adopted or publicly proposed (it being understood that the Company Board
Recommendation shall be deemed to have been modified in a manner adverse to Parent if it shall no
longer be unanimous). Nothing in this Agreement shall preclude (A)&nbsp;the Company from making any
public disclosure of any material facts, including the fact that an Acquisition Inquiry or
Acquisition Proposal has been submitted to the Company, if the Company Board determines in good
faith, after taking into account the advice of the Company&#146;s outside legal counsel, that the
failure to make such disclosure would be reasonably likely to constitute a breach of its fiduciary
duties to Company Stockholders under applicable Legal Requirements, or (B)&nbsp;the Company Board from
complying with Rules&nbsp;14d-9 and 14e-2(a) or Item 1012(a) of Regulation&nbsp;M-A under the Exchange Act
with regard to an Acquisition Proposal, except that the Company Board shall not be permitted to
withdraw the Company Board Recommendation or modify the Company Board Recommendation in a manner
adverse to Parent except as specifically provided in <U>Section&nbsp;5.2(c)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Notwithstanding anything to the contrary contained in this Agreement, at any time before
this Agreement is adopted by the Required Company Stockholder Vote, the Company Board
Recommendation may be withdrawn or modified in a manner adverse to Parent, if:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>(A)&nbsp;an offer that is a Superior Offer is made to the Company and is not withdrawn; (B)
such offer was not obtained or made as a direct or indirect result of a material breach by any
Acquired Corporation of this Agreement or the Confidentiality Agreement, or as a direct or indirect
result of a breach by any Acquired Corporation or any of its Representatives of the provisions set
forth in <U>Section&nbsp;4.3</U>; (C)&nbsp;the Company provides Parent, at least two Business Days prior to
any meeting of the Company Board at which such board of directors will consider such Superior Offer
(or such lesser period as is provided to the directors
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of the Company), with a written notice specifying the date and time of such meeting, the
reasons for holding such meeting, the terms and conditions of such Superior Offer (including a copy
of any draft definitive agreement relating to such Superior Offer to the extent such a draft
definitive agreement exists) and the identity of the Person making such Superior Offer; (D)&nbsp;the
Company Board determines in good faith, after consulting with the Company&#146;s outside legal counsel
and financial advisor, that, in light of such Superior Offer, the failure to so withdraw or modify
in a manner adverse to Parent the Company Board Recommendation would be reasonably likely to
constitute a breach of its fiduciary obligations to the Company Stockholders under applicable Legal
Requirements; (E)&nbsp;the Company Board Recommendation is not withdrawn or modified in a manner adverse
to Parent at any time within the period of five Business Days after Parent receives written notice
from the Company confirming that the Company Board has determined that the failure to withdraw or
modify in a manner adverse to Parent the Company Board Recommendation in light of such Superior
Offer would be reasonably likely to constitute a breach of its fiduciary obligations to the Company
Stockholders under applicable Legal Requirements; (F)&nbsp;during such five Business Day period, if
requested by Parent, the Company engages in good faith negotiations with Parent to amend this
Agreement in such a manner that the offer that was determined to constitute a Superior Offer no
longer constitutes a Superior Offer or that no withdrawal or modification in a manner adverse to
Parent of the Company Board Recommendation is required as a result of such offer; and (G)&nbsp;at the
end of such five Business Day period, such offer has not been withdrawn and continues to constitute
a Superior Offer and the Company Board determines in good faith, after consulting with the
Company&#146;s outside legal counsel and financial advisor, that the failure to withdraw or modify in a
manner adverse to Parent the Company Board Recommendation would continue to be reasonably likely to
constitute a breach of the fiduciary obligations of the Company Board to the Company Stockholders
under applicable Legal Requirements in light of such Superior Offer (taking into account any
changes to the terms of this Agreement or any alternative transaction proposed by Parent as a
result of the negotiations required by clause &#147;(F)&#148; or otherwise); or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>if: (A)&nbsp;there shall occur or arise after the date of this Agreement a material
development or material change in circumstances that relates to the Acquired Corporations but does
not relate to any Acquisition Proposal or Acquisition Inquiry (any such material development or
material change in circumstances unrelated to an Acquisition Proposal or Acquisition Inquiry being
referred to as an &#147;<B><I>Intervening Event</I></B>&#148;); (B)&nbsp;no Acquired Corporation, and no Representative of any
Acquired Corporation, had knowledge, as of the date of this Agreement, that such Intervening Event
was reasonably likely to occur or arise after the date of this Agreement; (C)&nbsp;the Company provides
Parent, at least two Business Days prior to any meeting of the Company Board at which such board of
directors will consider and determine whether such Intervening Event may require the Company to
withdraw or modify in a manner adverse to Parent the Company Board Recommendation (or such lesser
period as is provided to the directors), with a written notice specifying the date and time of such
meeting, the reasons for holding such meeting and a description of such Intervening Event; (D)&nbsp;the
Company Board determines in good faith, after consulting with its outside legal counsel, that, in
light of such Intervening Event, the failure to so withdraw or modify in a manner adverse to Parent
the Company Board Recommendation would be reasonably likely to constitute a breach of its fiduciary
obligations to the Company Stockholders under applicable Legal Requirements; (E)&nbsp;the Company Board
Recommendation is not withdrawn or modified in a manner adverse to Parent at any time within the
period of five Business Days after Parent receives written notice from the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company confirming that the Company Board has determined that the failure to withdraw or
modify in a manner adverse to Parent the Company Board Recommendation in light of such Intervening
Event would be reasonably likely to constitute a breach of its fiduciary obligations to the Company
Stockholders under applicable Legal Requirements; (F)&nbsp;during such five Business Day period, if
requested by Parent, the Company engages in good faith negotiations with Parent to amend this
Agreement in such a manner that no withdrawal or modification in a manner adverse to Parent to the
Company Board Recommendation is legally required as a result of such Intervening Event; and (G)&nbsp;at
the end of such five Business Day period, the Company Board determines in good faith, after
consulting with its outside legal counsel, that the failure to withdraw or modify in a manner
adverse to Parent the Company Board Recommendation would still be reasonably likely to constitute a
breach of the fiduciary obligations of the Company Board to the Company Stockholders under
applicable Legal Requirements in light of such Intervening Event (taking into account any changes
to the terms of this Agreement or any alternative transaction proposed by Parent as a result of the
negotiations required by clause &#147;(F)&#148; or otherwise).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Notwithstanding the terms of <U>Section&nbsp;5.2(a)</U>, if on a date for which the Company
Stockholders&#146; Meeting is scheduled, the Company has not received proxies representing a sufficient
number of shares of Company Common Stock to adopt this Agreement, whether or not a quorum is
present, the Company shall cause the Company Stockholders&#146; Meeting to be postponed or adjourned in
order to enable the additional time to solicit proxies from the Company Stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>Prior to a termination of this Agreement pursuant to <U>Section&nbsp;8.1</U>, the Company&#146;s
obligation to call, give notice of and hold the Company Stockholders&#146; Meeting in accordance with
<U>Section&nbsp;5.2(a)</U> shall not be limited or otherwise affected by the commencement, disclosure,
making, announcement or submission of any Superior Offer or other Acquisition Proposal, by any
Intervening Event or by any withdrawal or modification of the Company Board Recommendation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.3 Company Options and Company Warrants</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Each Company Option outstanding and unexercised as of immediately before the Effective
Time with a per share exercise price less than the Per Share Merger Consideration (an &#147;<B><I>In-the-Money
Option</I></B>&#148;) (i)&nbsp;will, automatically and without any required action on the part of the holder thereof,
be cancelled as of the Effective Time and converted into the right to receive an amount in cash
equal to the difference between (A)&nbsp;the Per Share Merger Consideration multiplied by the number of
shares of Company Common Stock underlying such In-the-Money Option, and (B)&nbsp;the aggregate exercise
price of such In-the-Money Option, and (ii)&nbsp;at the Effective Time, each In-the-Money Option will,
to the extent not vested, accelerate and become fully vested and exercisable as of immediately
prior to the Effective Time. Each Company Option, whether vested or unvested, outstanding and
unexercised as of immediately prior to the Effective Time that is not an In-the-Money Option will
automatically and without any required action on the part of the holder thereof, be cancelled as of
the Effective Time without any consideration payable in respect thereof. As soon as reasonably
practicable after the Effective Time (and if practicable by the next regularly scheduled payroll
date; <I>provided, however, </I>that it would be considered not practicable if such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">payroll date is within ten days following the Closing Date), Parent or the Surviving
Corporation shall pay over to each holder of In-the-Money Options the aggregate cash consideration
payable to such holder of In-the-Money Options pursuant to this <U>Section&nbsp;5.3(a)</U>. Such cash
consideration shall be rounded down to the nearest cent and Parent and the Surviving Corporation
shall be entitled to deduct and withhold from such cash consideration such amounts as may be
required to be deducted and withheld with respect to the making of such payment under the Code, the
rules and regulations promulgated thereunder, or any applicable Legal Requirement. To the extent
that amounts are so withheld by Parent or the Surviving Corporation, such withheld amounts shall be
treated for all purposes of this Agreement as having been paid to the holder of In-the-Money
Options in respect to which such deduction and withholding was made by Parent or the Surviving
Corporation, as the case may be.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Each outstanding Company Warrant, whether vested or unvested, as of immediately before the
Effective Time with a per share purchase price less than the Per Share Merger Consideration (the
&#147;<B><I>In-the-Money Warrants</I></B>&#148;) (i)&nbsp;will, automatically and without any required action on the part of the
holder thereof, be cancelled as of the Effective Time and converted into the right to receive an
amount in cash equal to the difference between (A)&nbsp;the Per Share Merger Consideration multiplied by
the number of shares of Company Common Stock underlying such Company Warrant, and (B)&nbsp;the aggregate
purchase price of such Company Warrant, and (ii)&nbsp;at the Effective Time, each In-the-Money Warrant
will, to the extent not vested, accelerate and become fully vested and exercisable as of
immediately prior to the Effective Time. Each Company Warrant, whether vested or unvested,
outstanding and unexercised as of immediately prior to the Effective Time outstanding and
unexercised as of immediately prior to the Effective Time that is not an In-the-Money Warrant will
automatically and without any required action on the part of the holder thereof, be cancelled as of
the Effective Time without any consideration payable in respect thereof. Parent and the Surviving
Corporation shall be entitled to deduct and withhold from such cash consideration such amounts as
may be required to be deducted and withheld with respect to the making of such payment under the
Code, the rules and regulations promulgated thereunder, or any applicable Legal Requirement. To
the extent that amounts are so withheld by Parent or the Surviving Corporation, such withheld
amounts shall be treated for all purposes of this Agreement as having been paid to the holder of
In-the-Money Warrants in respect to which such deduction and withholding was made by Parent or the
Surviving Corporation, as the case may be. To the extent required by the terms of the applicable
Company Warrant, prior to the Effective Time, the Company will provide each holder of Company
Warrants with a letter that conforms to the applicable notice and purchase requirements of such
holder&#146;s Company Warrant and sets forth the treatment of such holder&#146;s Company Warrants as
determined by this <U>Section&nbsp;5.3(b)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.4 Employee Benefits</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Parent agrees that all employees of the Company or its Subsidiaries who continue
employment with Parent, the Surviving Corporation or any Subsidiary of the Surviving Corporation
after the Effective Time (&#147;<B><I>Continuing Employees</I></B>&#148;) will be eligible to participate in: (i)&nbsp;Parent&#146;s
employee benefit plans and programs, including any equity incentive plan, pension plan, defined
benefit plan, defined contribution plan, Section 401(k) plan, bonus plan, profit sharing plan,
severance plan, medical plan, dental plan, life insurance plan, time-off programs and disability
plan, in each case to the same extent as similarly situated employees of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Parent; and (ii)&nbsp;such Company Employee Plans as are continued by the Company or any of its
Subsidiaries following the Closing Date, or are assumed by Parent (for the purposes of this
<U>Section&nbsp;5.3(b) </U>only, the plans referred to in clauses &#147;(i)&#148; and &#147;(ii)&#148; of this sentence
being referred to as &#147;<B><I>Specified Parent Benefit Plans</I></B>&#148;). Each Continuing Employee shall, to the
extent permitted by applicable Legal Requirements, receive full credit for purposes of eligibility,
vesting and vacation (but not for purposes of benefit accrual) under the Specified Parent Benefit
Plans in which such Continuing Employee participates for the years of continuous service by such
Continuing Employee recognized by the Company or its Subsidiaries prior to the Effective Time,
<I>provided, that, </I>such credit (A)&nbsp;does not result in a duplication of benefits, compensation,
incentive or otherwise and (B)&nbsp;does not result in an increase in the level of benefits beyond which
a similarly situated employee of Parent would be entitled. With respect to any welfare benefit
plans maintained by Parent for the benefit of Continuing Employees located in the United States,
subject to any applicable plan provisions, contractual requirements or Legal Requirements, Parent
shall use its commercially reasonable efforts to: (A)&nbsp;cause to be waived any eligibility
requirements or pre-existing condition limitations; and (B)&nbsp;give effect, in determining any
deductible maximum out-of-pocket limitations, to amounts paid by such Continuing Employees with
respect to substantially similar plans maintained by the Company or its Subsidiaries during the
plan year in which the Effective Time occurs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>If requested by Parent at least two Business Days prior to the Closing Date, the Company
shall take (or cause to be taken) all actions pursuant to resolutions of the Company Board
necessary or appropriate to terminate, effective no later than the day prior to the date on which
the Merger becomes effective, any Company Employee Plan that contains a cash or deferred
arrangement intended to qualify under Section 401(k) of the Code (a &#147;<B><I>Company </I></B><B><I>401(k)</I></B><B><I> Plan</I></B>&#148;). If the
Company is required to terminate any Company 401(k) Plan, then the Company shall provide to Parent
prior to the Closing Date written evidence of the adoption by the Company Board of resolutions
authorizing the termination of such Company 401(k) Plan (the form and substance of which
resolutions shall be subject to the prior review and approval of Parent, which approval shall not
be unreasonably withheld or delayed).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>To the extent any employee notification or consultation requirements are imposed by
applicable Legal Requirements with respect to the Contemplated Transactions, the Company shall
cooperate with Parent to ensure that such notification or consultation requirements are complied
with prior to the Effective Time. Prior to the Effective Time, the Company shall not communicate
with Continuing Employees regarding post-Closing employment matters, including post-Closing
employee benefits and compensation, without the prior written approval of Parent, which shall not
be unreasonably withheld.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.5 Indemnification of Officers and Directors</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Parent and the Company agree that all rights to exculpation, indemnification and
advancement of expenses existing as of the date of this Agreement in favor of the current or former
directors or officers of the Acquired Corporations (&#147;<B><I>Indemnified Parties</I></B>&#148;) as provided in their
respective certificates of incorporation or bylaws or in any indemnification agreement between an
Acquired Corporation and an Indemnified Party in his or her capacity as a director or officer of an
Acquired Corporation, as such agreement is in effect as of the date of this Agreement, shall
survive the Merger and shall continue in full force and effect,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">but only to the extent such rights to exculpation, indemnification and advancement of expenses
are available under and consistent with the laws of the jurisdictions of the relevant Acquired
Corporation. If, following the Effective Time, Parent takes any action, or fails to take any
action, that results in the inability of the Company to satisfy its obligations under this
<U>Section&nbsp;5.5</U>, Parent shall thereafter be liable for the obligations of the Surviving
Corporation pursuant to this <U>Section&nbsp;5.5</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>From the Effective Time through the sixth (6<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) anniversary of the date on
which the Effective Time occurs, the certificate of incorporation and bylaws of the Surviving
Corporation shall contain, and Parent shall cause the certificate of incorporation and bylaws of
the Surviving Corporation to so contain, provisions no less favorable with respect to
indemnification, advancement of expenses and exculpation of former directors and officers of the
Acquired Corporations than are set forth in the Company&#146;s certificate of incorporation and bylaws
as of the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Subject to the next sentence, the Surviving Corporation shall, at no expense to the
beneficiaries, either (i)&nbsp;maintain, and Parent shall cause the Surviving Corporation to maintain in
effect for six (6)&nbsp;years from the Effective Time the current policies of the directors&#146; and
officers&#146; liability insurance maintained by the Company and its Subsidiaries (the &#147;<B><I>Current D&#038;O
Insurance</I></B>&#148;) with respect to matters existing or occurring at or prior to the Effective Time
(including the Contemplated Transactions), so long as the annual premium therefor would not be in
excess of 250% of the last annual premium paid prior to the Effective Time (such 250%, the &#147;<B><I>Maximum
Premium</I></B>&#148;), or (ii)&nbsp;purchase a six (6)&nbsp;year extended reporting period endorsement with respect to
the Current D&#038;O Insurance (a &#147;<B><I>Reporting Tail Endorsement</I></B>&#148;) and maintain such endorsement in full
force and effect for its full term. If the Company&#146;s and its Subsidiaries&#146; existing insurance
expires, is terminated or canceled during such six-year period or exceeds the Maximum Premium, the
Surviving Corporation shall obtain, and Parent shall cause the Surviving Corporation to obtain, as
much directors&#146; and officers&#146; liability insurance as can be obtained for the remainder of such
period for an annualized premium not in excess of the Maximum Premium, on terms and conditions
(subject to the foregoing) no less advantageous to the Indemnified Parties than the Company&#146;s and
Subsidiaries&#146; existing directors&#146; and officers&#146; liability insurance. Notwithstanding anything to
the contrary in this Agreement, the Company may and may cause the Subsidiaries to, prior to the
Effective Time, purchase a Reporting Tail Endorsement; <I>provided</I>, <I>that</I>, the Company or Subsidiaries
do not pay more than the Maximum Premium for such Reporting Tail Endorsement, in which case,
provided that Parent causes the Surviving Corporation to maintain such Reporting Tail Endorsement
in full force and effect for its full term, Parent shall be relieved from its obligations under the
preceding two (2)&nbsp;sentences of this <U>Section&nbsp;5.5(c)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Parent shall pay all expenses, including reasonable attorneys&#146; fees, incurred by the
persons referred to in this <U>Section&nbsp;5.5</U> in connection with their enforcement of their
rights provided in this <U>Section&nbsp;5.5</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>The provisions of this <U>Section&nbsp;5.5</U> are intended to be in addition to, and Parent
shall, and shall cause the Surviving Corporation to, enforce and honor, to the fullest extent
permitted by law for a period of six (6)&nbsp;years from the Effective Time, the rights otherwise
available to the current officers and directors of the Company and its Subsidiaries by Legal
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Requirement, charter, bylaw or agreement, and shall operate for the benefit of, and shall be
enforceable by, each of the Indemnified Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.6 Regulatory Approvals and Related Matters</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Each party shall use reasonable best efforts to file, as promptly as practicable after the
date of this Agreement, all notices, reports and other documents required to be filed by such party
with any Governmental Body with respect to the Merger and the other Contemplated Transactions.
Without limiting the generality of the foregoing, the Company and Parent shall, as promptly as
practicable after the date of this Agreement, prepare and file the notifications required under the
HSR Act and under any other Legal Requirement that is designed to prohibit, restrict or regulate
actions having the purpose or effect of monopolization or restraint of trade (collectively,
&#147;<B><I>Antitrust Laws</I></B>&#148;) in connection with the Merger.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Parent, Merger Sub and the Company each shall promptly supply the other parties with any
information that may be required in order to effectuate any filings or applications pursuant to
<U>Section&nbsp;5.6(a)</U>. Except where prohibited by applicable Legal Requirements, and subject to
the Confidentiality Agreement, each of the Company and Parent shall, (i)&nbsp;consult with the other
party prior to taking a position with respect to any such filing, (ii)&nbsp;permit the other to review
and discuss in advance, and consider in good faith the views of the other in connection with, any
analyses, appearances, presentations, memoranda, briefs, white papers, arguments, opinions and
proposals before making or submitting any of the foregoing to any Governmental Body by or on behalf
of any party to this Agreement in connection with any investigations or proceedings in connection
with this Agreement or the Contemplated Transactions, (iii)&nbsp;coordinate with the other in preparing
and exchanging such information, and (iv)&nbsp;promptly provide the other (and its counsel) with copies
of all filings, presentations or submissions (and a summary of any oral presentations) made by such
party with any Governmental Body in connection with this Agreement or the Contemplated
Transactions; <I>provided, that, </I>with respect to any such filing, presentation or submission, each of
Parent and the Company need not supply the other (or its counsel) with copies (or, in case of oral
presentations, a summary) to the extent that any Legal Requirement applicable to such party
requires such party or its Subsidiaries to restrict or prohibit access to any such information or
to the extent required by any existing confidentiality or non-disclosure agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>The Company and Parent shall use reasonable best efforts to respond to and comply as
promptly as practicable with: (i)&nbsp;any inquiries or requests (including any &#147;second request&#148; for
information) received from the Federal Trade Commission or the U.S. Department of Justice for
additional information or documentation; and (ii)&nbsp;any inquiries or requests received from any state
attorney general, foreign antitrust authority or other Governmental Body in connection with
antitrust or related matters. Each party will notify the other promptly upon the receipt of (A)
any comments from any officials of any Governmental Body in connection with any filings made
pursuant to this Agreement, and (B)&nbsp;any request by any officials of any Governmental Body for
amendments or supplements to any filings made pursuant to, or information provided to comply in all
material respects with, any applicable Legal Requirements. Whenever any event occurs that is
required to be set forth in an amendment or supplement to any filing made pursuant to <U>Section
5.6(a)</U>, each party will promptly inform the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">other of such occurrence and cooperate in filing with the applicable Governmental Body such
amendment or supplement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Subject to the limitations set forth in <U>Section&nbsp;5.6(f)</U>, Parent and the Company
shall use reasonable best efforts to take, or cause to be taken, all actions necessary to
consummate the Merger and make effective the other Contemplated Transactions. Without limiting the
generality of the foregoing, each party to this Agreement: (i)&nbsp;shall make all filings (if any) and
give all notices (if any) required to be made and given by such party in connection with the Merger
and the other Contemplated Transactions; and (ii)&nbsp;shall use reasonable best efforts to obtain each
Consent (if any) required to be obtained (pursuant to any applicable Legal Requirement or Contract,
or otherwise) by such party in connection with the Merger or any of the other Contemplated
Transactions. At the request of Parent, the Company shall agree to divest, sell, dispose of, hold
separate or otherwise take or commit to take any other action with respect to any of the
businesses, product lines or assets of the Acquired Corporations, provided that any such action is
conditioned upon the consummation of the Merger. Each of Parent and the Company shall provide the
other party with a copy of each proposed filing with or other submission to any Governmental Body
relating to any of the Contemplated Transactions, and shall give the other party a reasonable time
prior to making such filing or other submission in which to review and comment on such proposed
filing or other submission. The Company shall promptly deliver to Parent a copy of each such filing
or other submission made, each notice given and each Consent obtained by any Acquired Corporation
during the Pre-Closing Period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>If any administrative or judicial action or proceeding is instituted (or threatened to be
instituted) challenging any transaction contemplated by this Agreement as violating any Antitrust
Law, Parent, Merger Sub and the Company shall use their reasonable best efforts to: (i)&nbsp;contest,
resist or resolve any such proceeding or action; and (ii)&nbsp;to have vacated, lifted, reversed or
overturned any injunction resulting from such proceeding or action, including, but not limited to,
entering into negotiations withy any applicable Governmental Body.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>Notwithstanding anything to the contrary contained in this <U>Section&nbsp;5.6</U> or
elsewhere in this Agreement, neither Parent nor Merger Sub shall have any obligation under this
Agreement to take any of the following actions, if Parent determines in good faith that taking such
actions would reasonably be expected to affect the business or interests of Parent, any of Parent&#146;s
Subsidiaries or any of the Acquired Corporations in any material adverse way: (i)&nbsp;to dispose of or
transfer or cause any of its Subsidiaries to dispose of or transfer any assets, or to commit to
cause any of the Acquired Corporations to dispose of or transfer any assets; (ii)&nbsp;to discontinue or
cause any of its Subsidiaries to discontinue offering any product or service, or to commit to cause
any of the Acquired Corporations to discontinue offering any product or service; (iii)&nbsp;to license
or otherwise make available, or cause any of its Subsidiaries to license or otherwise make
available to any Person any Intellectual Property or Intellectual Property Right, or to commit to
cause any of the Acquired Corporations to license or otherwise make available to any Person any
Intellectual Property or Intellectual Property Right; (iv)&nbsp;to hold separate or cause any of its
Subsidiaries to hold separate any assets or operations (either before or after the Closing Date),
or to commit to cause any of the Acquired Corporations to hold separate any assets or operations;
or (v)&nbsp;to make or cause any of its Subsidiaries to make any commitment, or to commit to cause any
of the Acquired Corporations to make any commitment (to any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Governmental Body or otherwise) regarding its future operations or the future operations of
any of the Acquired Corporations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.7 Confidentiality; Disclosure</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The parties to this Agreement acknowledge that Parent and the Company have previously
entered into the Confidentiality Agreement, which shall continue in full force and effect in
accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Parent and the Company shall consult with each other before issuing any press release or
otherwise making any public statement regarding the Merger or the Contemplated Transactions;
<I>provided, however, </I>that (i)&nbsp;Parent and the Company shall agree on the contents of the press release
announcing the execution of this Agreement and (ii)&nbsp;if Parent or the Company determines that a
press release or public announcement is required by any Legal Requirements, Parent or the Company
(as applicable) may make such press release or public announcement, in which case the disclosing
party shall use its commercially reasonable efforts to provide the other party with reasonable time
to comment on such release or announcement in advance of such issuance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Notwithstanding anything to the contrary contained in this <U>Section&nbsp;5.7</U>, the
obligations of Parent and the Company set forth in this <U>Section&nbsp;5.7</U> shall not apply with
respect to any public statement relating to the withdrawal or modification in a manner adverse to
Parent of the Company Board Recommendation that is permitted pursuant to <U>Section&nbsp;5.2(c)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.8 CHESS Depositary Interest</B>. Prior to the Closing Date, the Company will take all actions
that are necessary or appropriate to provide that the CDIs will, immediately prior to the Effective
Time or such other time as the parties agree with ASX and CDN (as applicable), be (a)&nbsp;suspended
from quotation on ASX and (b)&nbsp;cancelled or transmuted into the underlying shares of Company Common
Stock or Company Warrants (as the case may be) in accordance with the operating rules of the ASTC.
As soon as practicable after the Closing Date, the Surviving Corporation will apply to ASX to
delist the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.9 Section&nbsp;16 Matters</B>. Prior to the Effective Time, the Company shall be permitted to take
all such steps as may reasonably be necessary to cause the Contemplated Transactions, including any
dispositions of shares of Company Common Stock (including any Company Options or Company Warrants)
by each Person who is or will be subject to the reporting requirements of Section 16(a) of the
Exchange Act with respect to the Company, to be exempt under Rule&nbsp;16b-3 promulgated under the
Exchange Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.10 Resignation of Officers and Directors</B>. The Company shall use its reasonable best efforts
to obtain and deliver to Parent at or prior to the Effective Time the resignation of each officer
and director of each of the Acquired Corporations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.11 Stockholder Litigation</B>. The Company shall give Parent the opportunity to participate in
the defense or settlement of any stockholder litigation (including any class action or derivative
litigation) against the Company and/or any of its directors or officers relating to this Agreement,
the Merger or any of the other Contemplated Transactions, and no compromise or full or partial
settlement of any such litigation shall be agreed to by the Company without
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Parent&#146;s prior written consent. Any such participation by Parent shall be at
Parent&#146;s sole cost and expense.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.12 Employee Retention</B>. The Company shall cooperate and work with Parent to help Parent
identify employees of the Acquired Corporations to whom Parent may elect to offer continued
employment with the Surviving Corporation, such Subsidiaries or Parent. With respect to any
employee of the Acquired Corporations who receives an offer of employment from Parent or the
Surviving Corporation, the Company shall assist Parent with its efforts to enter into such
employment agreements as required by Parent with such employee as soon as practicable, but with
effectiveness expressly conditioned upon Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;6.</B> <FONT style="font-variant: SMALL-CAPS"><B>Conditions Precedent to Obligations of Parent and Merger Sub </B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obligations of Parent and Merger Sub to cause the Merger to be effected and otherwise
cause the Contemplated Transactions to be consummated are subject to the satisfaction or waiver, at
or prior to the Closing, of each of the following conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.1 Accuracy of Company Representations</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Each of the representations and warranties of the Company contained in <U>Section&nbsp;2</U>
(other than in <U>Section&nbsp;2.2(a)</U>, <U>Section&nbsp;2.2(c)</U>, <U>Section&nbsp;2.15(b)</U> and
<U>Section&nbsp;2.19</U>) shall have been accurate in all respects as of the date of this Agreement and
shall be accurate in all respects as of the Closing Date as if made on and as of the Closing Date
(except for any representations and warranties made as of a specific date, which shall have been
accurate in all respects only as of such date), except where the failure of such representations
and warranties to be accurate, individually or in the aggregate, would not have a Company Material
Adverse Effect; <I>provided, however</I>, that, for purposes of determining the accuracy of such
representations and warranties: (i)&nbsp;all &#147;Company Material Adverse Effect&#148; and other materiality
qualifications limiting the scope of such representations and warranties shall be disregarded; and
(ii)&nbsp;any update of or modification to the Company Disclosure Schedule made or purported to have
been made on or after the date of this Agreement shall be disregarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Each of the representations and warranties of the Company contained in <U>Section
2.15(b)</U> and <U>Section&nbsp;2.19</U> shall have been accurate in all respects as of the date of
this Agreement and shall be accurate in all respects as of the Closing Date as if made on and as of
the Closing Date; <I>provided, however, </I>that, for purposes of determining the accuracy of the
foregoing representations and warranties, any update of or modification to the Company Disclosure
Schedule made or purported to have been made on or after the date of this Agreement shall be
disregarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Each of the representations and warranties of the Company contained in <U>Section
2.2(a)</U> and <U>Section&nbsp;2.2(c)</U> shall have been accurate in all material respects as of the
date of this Agreement and shall be accurate in all material respects as of the Closing Date as if
made on and as of the Closing Date (except for any such representations and warranties made as of a
specific date, which shall have been accurate in all material respects only as of such date);
<I>provided, however, </I>that, for purposes of determining the accuracy of the foregoing
representations and warranties, any update of or modification to the Company Disclosure
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Schedule made or purported to have been made on or after the date of this Agreement shall be
disregarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.2 Performance of Covenants</B>. All of the covenants and obligations in this Agreement that the
Company is required to comply with or to perform at or prior to the Closing shall have been
complied with and performed in all material respects.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.3 Company Stockholder Approval</B>. This Agreement shall have been duly adopted by the Required
Company Stockholder Vote, and holders of less than 10% in the aggregate of the outstanding shares
of Company Common Stock shall have perfected their appraisal rights under Section&nbsp;262 of the DGCL
with respect to their shares of Company Common Stock or shall otherwise continue to have appraisal
rights under any applicable Legal Requirement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.4 Noncompetition Agreements</B>. The Noncompetition Agreements shall remain in full force and
effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.5 Company Officers&#146; Certificate</B>. Parent shall have received a certificate executed by a
duly authorized officer of the Company, in his or her capacity as such, confirming that the
conditions set forth in <U>Sections&nbsp;6.1</U> (Accuracy of Company Representations), <U>6.2</U>
(Performance of Covenants) and <U>6.3</U> (Company Stockholder Approval) have been satisfied.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.6 Regulatory Matters.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The waiting period applicable to the consummation of the Merger under the HSR Act shall
have expired or been terminated, and there shall not be in effect any voluntary agreement between
Parent or the Company and the Federal Trade Commission or the Department of Justice pursuant to
which Parent or the Company has agreed not to consummate the Merger for any period of time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Any waiting period applicable to the consummation of the Merger under any applicable
foreign antitrust or competition law or regulation or under any other foreign Legal Requirement
shall have expired or been terminated, except where the failure of any particular waiting period to
have expired or to have been terminated prior to the Closing would not reasonably be expected to
affect the business of Parent or any Acquired Corporation in any material adverse way.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Any Governmental Authorization or other Consent required to be obtained under any
applicable antitrust or competition law or regulation or under any other Legal Requirement shall
have been obtained and shall remain in full force and effect (except where the failure to have
obtained a particular Consent prior to the Closing would not reasonably be expected to affect the
business of Parent or any Acquired Corporation in any material adverse way), and no such
Governmental Authorization or other Consent shall require, contain or contemplate any term,
limitation, condition or restriction that Parent determines in good faith to be materially
burdensome.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.7 No Restraints</B>. No temporary restraining order, preliminary or permanent injunction or
other Order preventing the consummation of the Merger shall have been issued by
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any court of competent jurisdiction or other Governmental Body and remain in effect, and there shall not be any
Legal Requirement enacted or deemed applicable to the Merger that makes consummation of the Merger
illegal.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.8 No Governmental Litigation</B>. There shall not be pending or overtly threatened in writing
any Legal Proceeding brought or initiated (or overtly threatened in writing to be brought or
initiated) by a Governmental Body: (a)&nbsp;challenging or seeking to restrain or prohibit the
consummation of the Merger or any of the other Contemplated Transactions; (b)&nbsp;relating to the
Merger or any of the other Contemplated Transactions and seeking to obtain from Parent or any of
the Acquired Corporations any damages or other relief that may be material to Parent or the
Acquired Corporations; (c)&nbsp;seeking to prohibit or limit in any material respect Parent&#146;s ability to
vote, transfer, receive dividends with respect to or otherwise exercise ownership rights with
respect to the stock of the Surviving Corporation; (d)&nbsp;that would materially and adversely affect
the right or ability of Parent or any of the Acquired Corporations to own the assets or operate the
business of any of the Acquired Corporations; (e)&nbsp;seeking to compel any of the Acquired
Corporations, Parent or any Subsidiary of Parent to dispose of or hold separate any material assets
as a result of the Merger or any of the other Contemplated Transactions; or (f)&nbsp;seeking to impose
(or that would result in the imposition of) any criminal sanctions or criminal liability on Parent
or any of the Acquired Corporations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.9 No Company MAE</B>. Since the date of this Agreement, there shall not have occurred a Company
Material Adverse Effect and no event shall have occurred or circumstance shall exist that, in
combination with any other events or circumstances, would reasonably be expected to have or result
in any Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.10 Employee Retention</B>. Each of the persons listed on <U>Schedule&nbsp;6.10(a)</U> of the
Company Disclosure Schedule (the &#147;<B><I>Designated Employees</I></B>&#148;): (a)&nbsp;shall have executed an offer letter
in substantially the form attached as <U>Schedule&nbsp;6.10(b)</U> of the Company Disclosure Schedule
(with such changes thereto as may be proposed by Parent with respect to any one or more Designated
Employees; <I>provided, that, </I>with respect to any such Designated Employee, such changes are not
materially adverse to such Designated Employee), agreeing to remain employed by the Company or to
become employed by Parent following the Closing; and (b)&nbsp;shall, as of immediately prior to the
Effective Time, not have terminated or rescinded such acceptance; <I>provided, however, </I>that the
condition set forth in this <U>Section&nbsp;6.10</U> shall be deemed satisfied in respect of any
Designated Employee if (i)&nbsp;the employment of such Designated Employee with the Company has
terminated before the Closing due to the death or permanent and total disability (as defined in
Code Section&nbsp;22(e)(3)) of such Designated Employee, or (ii)&nbsp;Parent or the Company shall have failed
to include in such Designated Employee&#146;s offer letter an offer of a base salary and target cash
incentive compensation immediately following the Closing that is not less than his base salary and
target cash incentive compensation as of the date of this Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;7.</B> <FONT style="font-variant: SMALL-CAPS"><B>Conditions Precedent to Obligation of the Company </B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obligation of the Company to effect the Merger and otherwise consummate the Contemplated
Transactions is subject to the satisfaction or waiver, at or prior to the Closing, of the following
conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.1 Accuracy of Parent and Merger Sub Representations</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Each of the representations and warranties of Parent and Merger Sub contained in
<U>Section&nbsp;3</U> (other than in <U>Section&nbsp;3.3</U>) shall have been accurate in all respects as
of the date of this Agreement and shall be accurate in all respects as of the Closing Date as if
made on and as of the Closing Date (except for any representations and warranties made as of a
specific date, which shall have been accurate in all respects only as of such date), except where
the failure of such representations and warranties to be accurate, individually or in the
aggregate, would not have a Parent Material Adverse Effect; <I>provided, however</I>, that, for purposes
of determining the accuracy of such representations and warranties: (i)&nbsp;all &#147;Parent Material
Adverse Effect&#148; and other materiality qualifications limiting the scope of such representations and
warranties shall be disregarded; and (ii)&nbsp;any update of or modification to the Parent Disclosure
Schedule made or purported to have been made on or after the date of this Agreement shall be
disregarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Each of the representations and warranties of Parent and Merger Sub contained in
<U>Section&nbsp;3.3</U> shall have been accurate in all material respects as of the date of this
Agreement and shall be accurate in all material respects as of the Closing Date as if made on and
as of the Closing Date (except for any representations and warranties made as of a specific date,
which shall have been accurate in all material respects only as of such date); <I>provided, however,</I>
that, for purposes of determining the accuracy of the foregoing representations and warranties, any
update of or modification to the Parent Disclosure Schedule made or purported to have been made on
or after the date of this Agreement shall be disregarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.2 Performance of Covenants</B>. All of the covenants and obligations in this Agreement that
Parent and Merger Sub are required to comply with or to perform at or prior to the Closing shall
have been complied with and performed in all material respects.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.3 Company Stockholder Approval</B>. This Agreement shall have been duly adopted by the Required
Company Stockholder Vote.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.4 Parent Officer&#146;s Certificate</B>. The Company shall have received a certificate executed by a
duly authorized officer of Parent, in his or her capacity as such, confirming that the conditions
set forth in <U>Sections&nbsp;7.1</U> (Accuracy of Parent and Merger Sub Representations) and
<U>7.2</U> (Performance of Covenants) have been duly satisfied.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.5 HSR Waiting Period</B>. The waiting period applicable to the consummation of the Merger under
the HSR Act shall have expired or been terminated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.6 No Restraints</B>. No temporary restraining order, preliminary or permanent injunction or
other Order preventing the consummation of the Merger shall have been issued by any U.S.,
Australian or Irish court of competent jurisdiction or other U.S., Australian
or Irish
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Governmental Body and remain in effect, and there shall not be any U.S., Australian
or Irish Legal Requirement enacted or deemed applicable to the Merger that makes consummation of
the Merger illegal.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;8. </B><FONT style="font-variant: SMALL-CAPS"><B>Termination</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.1 Termination</B>. This Agreement may be terminated prior to the Effective Time (whether before
or after adoption of this Agreement by the Company Stockholders):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>by mutual written consent of Parent and the Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>by either Parent or the Company, if the Merger has not been consummated by March&nbsp;2, 2010
or any other date that Parent and the Company may agree upon in writing (the &#147;<B><I>Outside Date</I></B>&#148;);
<I>provided, however, </I>a party shall not be permitted to terminate this Agreement pursuant to this
<U>Section&nbsp;8.1(b) </U>if the failure to consummate the Merger by the Outside Date is principally
caused by the failure on the part of such party to perform any covenant or obligation in this
Agreement required to be performed by such party at or prior to the Effective Time;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>by either Parent or the Company, if a U.S., Australian or Irish court of competent
jurisdiction or other U.S., Australian or Irish Governmental Body shall have issued a final and
nonappealable Order, or shall have taken any other final and nonappealable action, having the
effect of permanently restraining, enjoining or otherwise prohibiting the consummation of the
Merger; <I>provided, however, </I>that (i)&nbsp;the party to this Agreement seeking to terminate this Agreement
pursuant to this <U>Section&nbsp;8.1(c)</U> shall have used commercially reasonable efforts to resist
or lift such Order; and (ii)&nbsp;a party shall not be permitted to terminate this Agreement pursuant to
this <U>Section&nbsp;8.1(c)</U> if the issuance of such Order is attributable to the failure of such
party to fulfill any of its obligations under this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>by either Parent or the Company, if: (i)&nbsp;the Company Stockholders&#146; Meeting (including any
adjournments and postponements thereof) shall have been held and completed and the Company
Stockholders shall have taken a final vote on a proposal to adopt this Agreement; and (ii)&nbsp;this
Agreement shall not have been adopted at the Company Stockholders&#146; Meeting (and shall not have been
adopted at any adjournment or postponement thereof) by the Required Company Stockholder Vote;
<I>provided, however, </I>that a party shall not be permitted to terminate this Agreement pursuant to this
<U>Section&nbsp;8.1(d)</U> if the failure to have this Agreement adopted by the Required Company
Stockholder Vote results from a failure on the part of such party to perform in any material
respect any covenant or obligation in this Agreement required to be performed by such party at or
prior to the Effective Time;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>by Parent (at any time prior to the adoption of this Agreement by the Required Company
Stockholder Vote) if (i)&nbsp;a Company Triggering Event shall have occurred, or (ii)&nbsp;the Company Board
Recommendation shall no longer be unanimous, or any reaffirmation of the Company Board
Recommendation shall not be unanimous;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>by Parent upon a breach of any representation, warranty, covenant or agreement on the part
of the Company set forth in this Agreement, or if any representation or
warranty of the Company shall have become untrue, in either case such that any of the
conditions
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">set forth in <U>Section&nbsp;6.1</U> or <U>Section&nbsp;6.2</U> would not be satisfied as of the
time of such breach or as of the time such representation or warranty shall have become untrue (it
being understood that, for purposes of determining the accuracy of such representations and
warranties as of the date of this Agreement or as of any subsequent date: (A)&nbsp;all &#147;Company Material
Adverse Effect&#148; and other materiality qualifications limiting the scope of such representations and
warranties shall be disregarded; and (B)&nbsp;any update of or modification to the Company Disclosure
Schedule made or purported to have been made on or after the date of this Agreement shall be
disregarded); <I>provided, that, </I>if any such breach of Company&#146;s representations and warranties as of
a date subsequent to the date of this Agreement or breach by the Company of a covenant or agreement
is curable by the Company within 30&nbsp;days (but no later than the Outside Date) and the Company is
continuing to exercise its reasonable best efforts to cure such breach, then Parent may not
terminate this Agreement under this <U>Section&nbsp;8.1(f)</U> until the earlier of the date 30&nbsp;days
after delivery of written notice from Parent to the Company of such breach or the Outside Date (it
being understood that Parent may not terminate this Agreement pursuant to this <U>Section
8.1(f)</U> if such breach by the Company is cured during such period in a manner that does not
result in a material breach of any covenant of the Company);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;</B>by the Company upon a breach of any representation, warranty, covenant or agreement on the
part of Parent or Merger Sub set forth in this Agreement, or if any representation or warranty of
Parent or Merger Sub shall have become untrue, in either case such that any of the conditions set
forth in <U>Section&nbsp;7.1</U> or <U>Section&nbsp;7.2</U> would not be satisfied as of the time of such
breach or as of the time such representation or warranty shall have become untrue (it being
understood that, for purposes of determining the accuracy of such representations and warranties as
of the date of this Agreement or as of any subsequent date: (A)&nbsp;all &#147;Parent Material Adverse
Effect&#148; and other materiality qualifications limiting the scope of such representations and
warranties shall be disregarded; and (B)&nbsp;any update of or modification to the Parent Disclosure
Schedule made or purported to have been made on or after the date of this Agreement shall be
disregarded); <I>provided, that, </I>if any such breach of Parent&#146;s or Merger Sub&#146;s representations and
warranties as of a date subsequent to the date of this Agreement or breach by Parent or Merger Sub
of a covenant or agreement is curable by Parent or Merger Sub within 30&nbsp;days (but no later than the
Outside Date) and Parent or Merger Sub is continuing to exercise its reasonable best efforts to
cure such breach, then the Company may not terminate this Agreement under this <U>Section
8.1(g)</U> until the earlier of the date 30&nbsp;days after delivery of written notice from the Company
to Parent of such breach or the Outside Date (it being understood that the Company may not
terminate this Agreement pursuant to this <U>Section&nbsp;8.1(g)</U> if such breach by Parent or Merger
Sub is cured during such period in a manner that does not result in a material breach of any
covenant of Parent or Merger Sub);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(h)&nbsp;</B>by the Company, if: (A)&nbsp;an offer that is a Superior Offer is made to the Company and is
not withdrawn; (B)&nbsp;such offer was not obtained or made as a direct or indirect result of a material
breach by any Acquired Corporation of this Agreement or the Confidentiality Agreement, or as a
direct or indirect result of a breach by any Acquired Corporation or any of its Representatives of
any of the provisions set forth in <U>Section&nbsp;4.3</U>; (C)&nbsp;the Company provides Parent, at least
two Business Days prior to any meeting of the Company Board at which such board of directors will
consider causing the Company to enter into a binding definitive acquisition agreement concerning a
transaction that constitutes such Superior Offer
(but not more than one Business Day after any director of the Company is first notified of
such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">meeting), with a written notice specifying the date and time of such meeting, the reasons for
holding such meeting, the terms and conditions of such Superior Offer (including a copy of any
draft definitive agreement relating to such Superior Offer to the extent such a draft definitive
agreement exists) and the identity of the Person making such Superior Offer; (D)&nbsp;the Company Board
determines in good faith, after consulting with the Company&#146;s outside legal counsel and financial
advisor, that, in light of such Superior Offer, the failure to terminate this Agreement in order to
permit the Company to enter into such binding definitive acquisition agreement would be reasonably
likely to constitute a breach of its fiduciary obligations to the Company Stockholders under
applicable Legal Requirements; (E)&nbsp;such binding definitive acquisition agreement is not entered
into at any time within the period of three Business Days after Parent receives written notice from
the Company confirming that the Company Board has determined that the failure to terminate this
Agreement in order to permit the Company to enter into such binding definitive acquisition
agreement would be reasonably likely to constitute a breach of its fiduciary obligations to the
Company Stockholders under applicable Legal Requirements; (F)&nbsp;during such three Business Day
period, if requested by Parent, the Company engages in good faith negotiations with Parent to amend
this Agreement in such a manner that the offer that was determined to constitute a Superior Offer
no longer constitutes a Superior Offer or that no termination of this Agreement in order to permit
the Company to enter into such binding definitive acquisition agreement is required as a result of
such offer; and (G)&nbsp;at the end of such three Business Day period, the Company Board determines in
good faith, after consulting with the Company&#146;s outside legal counsel and financial advisor, that
the failure to terminate this Agreement in order to permit the Company to enter into such binding
definitive acquisition agreement would continue to be reasonably likely to constitute a breach of
the fiduciary obligations of the Company Board to the Company Stockholders under applicable Legal
Requirements in light of such Superior Offer (taking into account any changes to the terms of this
Agreement or any alternative transaction proposed by Parent as a result of the negotiations
required by clause &#147;(F)&#148; or otherwise); <I>provided, that, </I>for the avoidance of doubt, the Company may
provide the notices required by <U>Section&nbsp;5.2(c)(i)</U> and this <U>Section&nbsp;8.1(h)</U>
concurrently and the five and three day notice periods required by such respective sections may run
concurrently; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>by Parent if a Company Material Adverse Effect shall have occurred following the date of
this Agreement.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notwithstanding anything to the contrary contained in this <U>Section&nbsp;8.1</U>, this Agreement may
not be terminated by any party unless any fee required to be paid (or caused to be paid) by such
party at or prior to the time of such termination pursuant to <U>Section&nbsp;8.4</U> shall have been
paid in full.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.2 Effect of Termination</B>. In the event of the termination of this Agreement as provided in
<U>Section&nbsp;8.1</U>, this Agreement shall be of no further force or effect; <I>provided, however,</I>
that: (i)&nbsp;this <U>Section&nbsp;8.2</U>, <U>Section&nbsp;8.3</U>, <U>Section&nbsp;8.4</U>, and <U>Section&nbsp;9</U>
shall survive the termination of this Agreement and shall remain in full force and effect, (ii)&nbsp;the
Confidentiality Agreement shall remain in full force and effect in accordance with its terms, and
(iii)&nbsp;the termination of this Agreement shall not relieve any party from any liability for any
intentional or willful and material breach of any representation, warranty, covenant, obligation or
other provision contained in this Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.3 Expenses</B>. Except as set forth in this <U>Section&nbsp;8.3</U>, all fees and expenses incurred
in connection with this Agreement and the Contemplated Transactions shall be paid (or caused to be
paid) by the party incurring such expenses, whether or not the Merger is consummated. If this
Agreement is terminated by Parent or the Company pursuant to <U>Section&nbsp;8.1(d)</U>, then the
Company shall as promptly as practicable in light of the Company&#146;s then-current cash position (but
in any event within 60 Business Days following such termination) reimburse Parent for all
reasonable and documented out-of-pocket fees and expenses (including all attorneys&#146; fees,
accountants&#146; fees, financial advisory fees and filing fees) that have been incurred or paid or that
may become payable by or on behalf of Parent or any of its Subsidiaries (i)&nbsp;in connection with the
preparation, negotiation and performance of this Agreement and all related agreements and
documents, (ii)&nbsp;in connection with the due diligence investigation conducted with respect to the
Acquired Corporations, and (iii)&nbsp;in connection with all transactions contemplated by this
Agreement, up to a maximum of $2,000,000.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.4 Termination Fee</B>. If this Agreement is terminated: (a)&nbsp;by Parent pursuant to <U>Section
8.1(e)</U>; (b)&nbsp;pursuant to <U>Section&nbsp;8.1(d)</U>, and (i)&nbsp;prior to the adoption of this Agreement
by the Required Company Stockholder Vote, an Acquisition Proposal shall have been publicly
disclosed, announced, commenced, submitted or made and not withdrawn, at least five Business Days
prior to the date of the Company Stockholders&#146; Meeting, and (ii)&nbsp;by the first anniversary of such
termination, either (A)&nbsp;the Company consummates a Specified Acquisition Transaction or (B)&nbsp;the
Company enters into a definitive agreement relating to a Specified Acquisition Transaction and,
following such first anniversary, the Specified Acquisition Transaction to which such definitive
agreement relates (or any other Specified Acquisition Transaction among or involving the parties to
such definitive agreement or any of such parties&#146; affiliates) is consummated; or (c)&nbsp;by the Company
pursuant to <U>Section&nbsp;8.1(h)</U>; then the Company shall pay Parent a nonrefundable fee equal to
$10,000,000 <I>minus </I>any amount actually previously paid by the Company to Parent as reimbursement
pursuant to <U>Section&nbsp;8.3</U>. Such fee shall be paid in immediately available funds and shall
be due and payable on the date that is (A)&nbsp;two (2)&nbsp;Business Days after the date of termination in
the event of a termination by Parent pursuant to <U>Section&nbsp;8.1(e)</U>, (B)&nbsp;on or prior to the
date on which the applicable Specified Acquisition Transaction is consummated in the event of a
termination pursuant to <U>Section&nbsp;8.1(d)</U>, or (C)&nbsp;prior to the effectiveness of any
termination pursuant to <U>Section&nbsp;8.1(h)</U>. &#147;<B><I>Specified Acquisition Transaction</I></B>&#148; shall have the
same meaning as the term &#147;Acquisition Transaction,&#148; except that, solely for purposes of the
definition of Specified Acquisition Transaction, all references to &#147;15%&#148; or &#147;85%&#148; in the definition
of &#147;Acquisition Transaction&#148; shall be deemed to refer instead to &#147;50%&#148;. If the Company fails to
pay when due any amount payable under <U>Section&nbsp;8.3</U> or this <U>Section&nbsp;8.4</U>, then (i)&nbsp;the
Company shall reimburse Parent for all costs and expenses (including fees and disbursements of
legal counsel) incurred in connection with the collection of such overdue amount and the
enforcement by Parent of its rights under <U>Section&nbsp;8.3</U> or this <U>Section&nbsp;8.4</U>, and (ii)
the Company shall pay to Parent interest on such overdue amount (for the period commencing as of
the date such overdue amount was originally required to be paid and ending on the date such overdue
amount is actually paid to Parent in full) at a rate per annum equal to the &#147;prime rate&#148; (as
announced by Bank of America or any successor thereto) in effect on the date such amount was
originally required to be paid.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;9. </B><FONT style="font-variant: SMALL-CAPS"><B>Miscellaneous Provisions</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.1 Amendment</B>. This Agreement may be amended with the approval of Parent and the Company&#146;s
respective boards of directors at any time (whether before or after this Agreement is adopted by
the Company Stockholders); <I>provided, however, </I>that after any such adoption of this Agreement by the
Company Stockholders, no amendment shall be made which pursuant to applicable Legal Requirements
requires further approval of the Company Stockholders without the further approval of the Company
Stockholders. This Agreement may not be amended except by an instrument in writing signed on
behalf of each of the parties to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.2 Extension; Waiver</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Subject to <U>Sections&nbsp;9.2(b)</U> and <U>9.2(c)</U>, at any time prior to the Effective
Time, Parent and Merger Sub on the one hand and the Company on the other hand may: (i)&nbsp;extend the
time for the performance of any of the obligations or other acts of the other party; (ii)&nbsp;waive any
inaccuracy in or breach of any representation, warranty, covenant or obligation of the other party
in this Agreement or in any document delivered pursuant to this Agreement; and (iii)&nbsp;waive
compliance with any covenant, obligation or condition for the benefit of such party contained in
this Agreement. The agreement of Parent to any extension or waiver shall be deemed to be the
agreement of Merger Sub to such extension or waiver.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>No failure on the part of any party to exercise any power, right, privilege or remedy
under this Agreement, and no delay on the part of any party in exercising any power, right,
privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege
or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall
preclude any other or further exercise thereof or of any other power, right, privilege or remedy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>No party shall be deemed to have waived any claim arising out of this Agreement, or any
power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power,
right, privilege or remedy is expressly set forth in a written instrument duly executed and
delivered on behalf of such party; and any such waiver shall not be applicable or have any effect
except in the specific instance in which it is given.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.3 No Survival of Representations and Warranties</B>. None of the representations and warranties
contained in this Agreement or in any certificate delivered pursuant to this Agreement shall
survive the Merger.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.4 Entire Agreement; Counterparts; Exchanges by Facsimile or Electronic Delivery</B>. This
Agreement and the other agreements, exhibits and disclosure schedules referred to herein constitute
the entire agreement and supersede all prior agreements and understandings, both written and oral,
among or between any of the parties with respect to the subject matter hereof and thereof;
<I>provided, however</I>, that the Confidentiality Agreement shall not be superseded and shall remain in
full force and effect in accordance with its terms. This Agreement may be executed in several
counterparts, each of which shall be deemed an original and all of which shall constitute one and
the same instrument. The exchange of a fully
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">executed Agreement (in counterparts or otherwise) by facsimile or by electronic delivery in .pdf format shall be sufficient to bind the parties to the terms and conditions of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.5 Applicable Law; Jurisdiction</B>. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise
govern under applicable principles of conflicts of laws thereof. In any action between any of the
parties arising out of or relating to this Agreement or any of the Contemplated Transactions: (a)
each of the parties irrevocably and unconditionally consents and submits to the exclusive
jurisdiction and venue of the Chancery Court of the State of Delaware; and (b)&nbsp;each of the parties
irrevocably waives the right to trial by jury.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.6 Attorneys&#146; Fees</B>. In any action at law or suit in equity to enforce this Agreement or the
rights of any of the parties hereunder, the prevailing party in such action or suit shall be
entitled to receive a reasonable sum for its attorneys&#146; fees and all other reasonable costs and
expenses incurred in such action or suit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.7 Assignability; No Third Party Rights</B>. This Agreement shall be binding upon, and shall be
enforceable by and inure solely to the benefit of, the parties to this Agreement and their
respective successors and assigns; <I>provided, however, </I>that neither this Agreement nor any party&#146;s
rights or obligations hereunder may be assigned or delegated by such party without the prior
written consent of the other parties, and any attempted assignment or delegation of this Agreement
or any of such rights or obligations by any party without the prior written consent of the other
parties shall be void and of no effect, <I>provided, however</I>, that either or both Parent and Merger
Sub may assign their rights under this Agreement to any wholly owned Subsidiary of Parent
(<I>provided, that, </I>no such assignment shall relieve Parent of any obligation it may have hereunder).
Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person
(other than the parties to this Agreement) any right, benefit or remedy of any nature whatsoever
under or by reason of this Agreement, except that, from and after the Effective Time, the
provisions of <U>Section&nbsp;1</U> shall be for the benefit of holders of Company Common Stock, and
the provisions of <U>Section&nbsp;5.5</U> shall be for the benefit of the Indemnified Parties. In the
event that the Company brings a Legal Proceeding for monetary damages for breach of this Agreement
in which it is held that the right to obtain such monetary damages (including damages based on the
loss of economic benefits of the Contemplated Transactions to the holders of Company Common Stock,
Company Options and Company Warrants, if determined appropriate) is solely held by the holders of
Company Common Stock, Company Options and Company Warrants, then such rights of the holders of
Company Common Stock, Company Options and Company Warrants may be enforced on their behalf by the
Company as agent for the holders of Company Common Stock, Company Options and Company Warrants.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.8 Notices</B>. All notices, requests, demands and other communications under this Agreement
shall be in writing and shall be deemed to have been duly given or made as follows: (a)&nbsp;if sent by
registered or certified mail in the United States return receipt requested, upon receipt; (b)&nbsp;if
sent designated for overnight delivery by nationally recognized overnight air courier (such as UPS
or Federal Express), two (2)&nbsp;Business Days after mailing; (c)&nbsp;if sent by facsimile transmission
before 5:00 p.m., Pacific time, when transmitted and receipt is confirmed; (d)&nbsp;if sent by facsimile
transmission after 5:00 p.m., Pacific time, and receipt is confirmed, on the
following Business Day; and (e)&nbsp;if otherwise actually personally delivered, when delivered;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>provided</I>, <I>that</I>, such notices, requests, demands and other communications are delivered to the
address set forth below, or to such other address as any party shall provide by like notice to the
other parties to this Agreement:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to Parent or Merger Sub:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="89%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LEO Pharma A/S</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Industriparken 55</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DK &#151; 2750 Bellerup</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Nina Solver Henning</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 45-72263295</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with a copy (which shall not constitute notice) to:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="89%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cooley Godward Kronish LLP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Five Palo Alto Square</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3000 El Camino Real</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Palo Alto, CA 94306</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Glen Y. Sato</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650)&nbsp;849-7400</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to the Company:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="89%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Peplin, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6475 Christie Avenue</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Suite&nbsp;300</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Emeryville, CA 94608</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Thomas Wiggans</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;David Smith</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (510)&nbsp;653-9704</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with copies (which shall not constitute notice) to:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="89%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fenwick &#038; West LLP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">555 California St., 12<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">San Francisco, CA 94104</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Douglas N. Cogen</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;David K. Michaels</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (415)&nbsp;281-1350</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.9 Severability</B>. Any term or provision of this Agreement that is invalid or unenforceable in
any situation in any jurisdiction shall not affect the validity or enforceability of the remaining
terms and provisions of this Agreement or the validity or enforceability of the offending term or
provision in any other situation or in any other jurisdiction. If a final judgment of a court of
competent jurisdiction declares that any term or provision of this Agreement is invalid or
unenforceable, the parties agree that the court making
such determination shall have the power to limit such term or provision, to delete specific
words or phrases or to replace such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">term or provision with a term or provision that is valid and
enforceable and that comes closest to expressing the intention of the invalid or unenforceable term
or provision, and this Agreement shall be valid and enforceable as so modified. In the event such
court does not exercise the power granted to it in the prior sentence, the parties agree to replace
such invalid or unenforceable term or provision with a valid and enforceable term or provision that
will achieve, to the extent possible, the economic, business and other purposes of such invalid or
unenforceable term or provision.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.10 Remedies</B>. Except as otherwise provided herein, any and all remedies herein expressly
conferred upon a party hereto shall be deemed cumulative with and not exclusive of any other remedy
conferred hereby, or by law or equity upon such party, and the exercise by a party hereto of any
one remedy shall not preclude the exercise of any other remedy and nothing in this Agreement shall
be deemed a waiver by any party of any right to specific performance or injunctive relief. Because
the parties hereto agree that irreparable damage would occur if a provision of this Agreement were
not performed in accordance with the terms hereof, it is accordingly agreed that the parties shall
be entitled to seek and obtain, if available, an injunction or injunctions to prevent breaches of
this Agreement and to enforce specifically the terms and provisions hereof, and the parties hereby
waive the requirement of any posting of a bond in connection with the remedies described herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.11 Construction</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>For purposes of this Agreement, whenever the context requires: the singular number shall
include the plural, and vice versa; the masculine gender shall include the feminine and neuter
genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender
shall include masculine and feminine genders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The parties agree that any rule of construction to the effect that ambiguities are to be
resolved against the drafting party shall not be applied in the construction or interpretation of
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>As used in this Agreement, the words &#147;include&#148; and &#147;including,&#148; and variations thereof,
shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the
words &#147;without limitation.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Except as otherwise indicated, all references in this Agreement to &#147;Sections,&#148; &#147;Exhibits&#148;
and &#147;Schedules&#148; are intended to refer to Sections of this Agreement and Exhibits or Schedules to
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>The bold-faced headings contained in this Agreement are for convenience of reference only,
shall not be deemed to be a part of this Agreement and shall not be referred to in connection with
the construction or interpretation of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>For purposes of <U>Section&nbsp;8</U>, references to the failure of a party to perform its
covenants or obligations in this Agreement shall, in the case of Parent, include the failure of
Merger Sub to perform its covenants or obligations in this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;</B>To the extent this Agreement refers to information or documents to be made available,
delivered, produced or provided by the Company to Parent or Merger Sub, the Company shall be deemed
to have satisfied such obligation if the Company has made such information or document available by
(i)&nbsp;posting such information or document at least two Business Days prior to the date of this
Agreement (or such shorter period as may be specified by email notice by the Company or its
Representative to Parent or its Representative prior to the date of this Agreement, with respect to
any specific information or documents posted within such two day period) to the &#147;electronic data
room&#148; maintained by the Company and accessible by Parent or any of its Representatives for purposes
of the Contemplated Transactions or (ii)&nbsp;delivering such information or document to Parent or its
Representatives at least two Business Days prior to the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(h)&nbsp;</B>References to &#147;$&#148; or &#147;dollars&#148; refer to United States dollars unless otherwise noted.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>&#091;Remainder of Page Intentionally Left Blank&#093;</B></FONT>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->58<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>In Witness Whereof</B></FONT>, the parties have caused this <FONT style="font-variant: SMALL-CAPS"><B>Agreement and Plan of
Merger</B></FONT> to be executed as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Peplin, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Wiggans
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Wiggans
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>&#091;Signature Page to Agreement and Plan of Merger&#093;</B></FONT>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>In Witness Whereof</B></FONT>, the parties have caused this <FONT style="font-variant: SMALL-CAPS"><B>Agreement and Plan of
Merger</B></FONT> to be executed as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Plant Acquisition Sub, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gitte P. Aabo
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gitte P. Aabo</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>&#091;Signature Page to Agreement and Plan of Merger&#093;</B></FONT>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>In Witness Whereof</B></FONT>, the parties have caused this <FONT style="font-variant: SMALL-CAPS"><B>Agreement and Plan of
Merger</B></FONT> to be executed as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Leo Pharma A/S</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top" style="font-size: 10pt; border-bottom: 1px solid #000000">/s/ Gitte P. Aabo
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gitte P. Aabo</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"> President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
<TD align="left" valign="top" style="font-size: 10pt; border-bottom: 1px solid #000000">/s/ John Mehlbye
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">John Mehlbye&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>Executive Vice-President, Plants &#38; Manufacturing&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>&#091;Signature Page to Agreement and Plan of Merger&#093;</B></FONT>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;A</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Certain Definitions</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of the Agreement (including this <U>Exhibit&nbsp;A</U>):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Acquired Corporations</B>. &#147;Acquired Corporations&#148; means the Company and the Company&#146;s
Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Acquisition Inquiry</B>. &#147;Acquisition Inquiry&#148; means any inquiry of, indication of interest to or
communication to the Company (other than by Parent or any of its Affiliates or Representatives on
behalf of Parent) concerning an Acquisition Transaction or that would reasonably be expected to
lead to an Acquisition Proposal, but which is not an Acquisition Proposal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Acquisition Proposal</B>. &#147;Acquisition Proposal&#148; means any offer or proposal (other than an offer
or proposal made or submitted by Parent or any of its Affiliates or Representatives on behalf of
Parent) contemplating or otherwise relating to any Acquisition Transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Acquisition Transaction</B>. &#147;Acquisition Transaction&#148; means with respect to the Company, any
transaction or series of transactions (other than the Merger) involving:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>any acquisition or purchase by any Person or group (as defined in the Exchange Act and the
rules promulgated thereunder) of more than a 15% interest in the total outstanding voting
securities of the Company or any tender offer or exchange offer that if consummated would result in
any Person or group (as defined in the Exchange Act and the rules promulgated thereunder)
beneficially owning securities representing 15% or more of the total outstanding voting power of
the Company, or any merger, consolidation, business combination, share exchange, issuance of
securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange
offer or similar transaction (i)&nbsp;in which any of the Acquired Corporations is a constituent
corporation, (ii)&nbsp;pursuant to which the Company Stockholders immediately preceding such transaction
would hold securities representing less than 85% of the total outstanding voting power of the
surviving or resulting entity of such transaction (or parent entity of such surviving or resulting
entity) immediately following the consummation of such transaction or (iii)&nbsp;in which any of the
Acquired Corporations issues securities representing more than 15% of the outstanding securities of
any class of voting securities of any of the Acquired Corporations;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>any sale, lease, exchange, transfer, exclusive license or disposition of any business or
businesses or assets that constitute or account representing 15% or more of the aggregate fair
market value of the consolidated assets of the Company and its Subsidiaries taken as a whole; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>any liquidation or dissolution of any of the Acquired Corporations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Affiliate</B>. &#147;Affiliate&#148; shall have the meaning ascribed to such term under Rule&nbsp;12b-2 of the
General Rules and Regulations under the Exchange Act.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ASIC</B>. &#147;ASIC&#148; means the Australian Securities and Investments Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ASTC</B>. &#147;ASTC&#148; means ASX Settlement and Transfer Corporation Pty Ltd ACN 008 504 532.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ASX</B>. &#147;ASX&#148; means ASX Limited ACN 008 624 691 or the Australian Securities Exchange, as the
context requires.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ASX Listing Rules</B>. &#147;ASX Listing Rules&#148; means the official listing rules of ASX.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Business Day</B>. &#147;Business Day&#148; means a day (a)&nbsp;other than Saturday or Sunday and (b)&nbsp;on which
commercial banks are open for business in San Francisco, California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>CDIs</B>. &#147;CDIs&#148; means Shares CDIs and Options CDIs, collectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>CDN</B>. &#147;CDN&#148; means CHESS Depositary Nominees Pty Ltd ACN 071 346 506.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>CHESS</B>. &#147;CHESS&#148; means the clearing house electronic sub-register system of share transfers
operated by ASTC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Code</B>. &#147;Code&#148; means the United States Internal Revenue Code of 1986, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Affiliate</B>. &#147;Company Affiliate&#148; means any Person under common control with the Company
within the meaning of Section&nbsp;414(b), Section&nbsp;414(c), Section 414(m) or Section 414(o) of the Code,
and the regulations issued thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company ASX Documents</B>. &#147;Company ASX Documents&#148; means all proxy statements, reports,
schedules, forms, statements or other documents, including all amendments thereto, required to be
filed by the Company under the Corporations Act or the ASX Listing Rules since January&nbsp;1, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Board</B>. &#147;Company Board&#148; means the Company&#146;s board of directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Class&nbsp;B Common Stock</B>. &#147;Company Class&nbsp;B Common Stock&#148; means the Class&nbsp;B Common Stock,
$0.001 par value per share, of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Common Stock</B>. &#147;Company Common Stock&#148; means the Common Stock, $0.001 par value per
share, of the Company, including common stock in respect of which Share CDIs have been issued.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Contract</B>. &#147;Company Contract&#148; means any Contract: (a)&nbsp;to which any of the Acquired
Corporations is a party; (b)&nbsp;by which any of the Acquired Corporations or any Company Owned IP or
Company In-Licensed IP or any other asset of any of the Acquired Corporations is or may become
bound or under which any of the Acquired Corporations has, or may become subject to, any
obligation; or (c)&nbsp;under which any of the Acquired Corporations has or may acquire any right or
interest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Disclosure Schedule</B>. &#147;Company Disclosure Schedule&#148; means the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Disclosure Schedule and exhibits thereto that the Company delivers to Parent upon the
execution of the Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Employee</B>. &#147;Company Employee&#148; means any director, officer or employee of the Company
or any of its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Employee Agreement</B>. &#147;Company Employee Agreement&#148; means any employment, severance,
retention, transaction bonus, change in control, consulting, or other similar Contract between: (a)
the Company or any of its Subsidiaries or any current Company Affiliate; and (b)&nbsp;any Company
Employee, other than any such Contract that is terminable &#147;at will&#148; (or following a notice period
imposed by applicable Legal Requirements) without any obligation on the part of the Company or any
of its Subsidiaries or any Company Affiliate to make any severance, termination, change in control
or similar payment or to provide any benefit, other than severance payments required to be made by
the Company or any of its Subsidiaries under applicable foreign law (which excepted Contracts shall
also not constitute Company Employee Plans hereunder).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Employee Plan</B>. &#147;Company Employee Plan&#148; means any plan, program, policy, practice or
Contract providing for compensation, severance, termination pay, deferred compensation, performance
awards, stock or stock-related awards, fringe benefits, retirement benefits or other benefits or
remuneration of any kind, whether or not in writing and whether or not funded, including each
&#147;employee benefit plan,&#148; within the meaning of Section&nbsp;3(3) of ERISA (whether or not ERISA is
applicable to such plan) that is maintained or contributed to, or required to be maintained or
contributed to, by the Company, any of its Subsidiaries, or any Company Affiliate for the benefit
of any Company Employee; <I>provided, however, </I>that a Company Employee Agreement shall not be
considered a Company Employee Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company In-Licensed IP</B>. &#147;Company In-Licensed IP&#148; means all Intellectual Property Rights that
are licensed by the Company and its Subsidiaries and that are used or contemplated to be used in
the conduct the business of the Company and its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Material Adverse Effect</B>. &#147;Company Material Adverse Effect&#148; means any effect, change,
event or circumstance (&#147;<B><I>Effect</I></B>&#148;) that, considered together with all other Effects, is or would
reasonably be expected to be or to become materially adverse to, or has or would reasonably be
expected to have or result in a material adverse effect on: (a)&nbsp;the business, financial condition,
capitalization or results of operations of the Company and its Subsidiaries taken as a whole, (b)
the Company&#146;s ability to consummate the Merger or (c)&nbsp;Parent&#146;s ability to vote, transfer, receive
dividends with respect to or otherwise exercise ownership rights with respect to any shares of the
stock of the Surviving Corporation; <I>provided, however, </I>that, in no event shall any of the
following, alone or in combination, be deemed to constitute, nor shall any of the following be
taken into account in determining whether there has occurred, a Company Material Adverse Effect:
(i)&nbsp;Effects resulting from changes since the date of the Agreement in conditions, including
regulatory review standards, generally affecting the industries in which the Company or any of its
Subsidiaries participates or the U.S., Australian or global economy or capital markets as a whole,
to the extent that such conditions do not have a substantially disproportionate impact on the
Company and its Subsidiaries taken as a whole when compared to other firms in the industries in
which the Company or any of its Subsidiaries participates; (ii)
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Effects resulting from acts of war, armed hostilities or terrorism since the date of the Agreement;
(iii)&nbsp;changes in the trading price or trading volume of Company Common Stock or CDIs in and of
themselves (it being understood, however, that the facts or circumstances giving rise to any such
change in such trading price or trading volume may be taken into account in determining whether
there has been or would be a Company Material Adverse Effect); (iv)&nbsp;Effects resulting from the
announcement or pendency of the Merger and the Contemplated Mergers to the extent that the Company
conclusively demonstrates that such Effects are directly and exclusively attributable to the
announcement or pendency of the Merger and the Contemplated Transactions; (v)&nbsp;any failure by the
Company to meet internal or published third party projections, estimates or forecasts, in and of
itself (it being understood, however, that the facts or circumstances giving rise to any such
failure may be taken into account in determining whether there has been or would be a Company
Material Adverse Effect); (vi)&nbsp;Company stockholder class action or derivative litigation commenced
against the Company since the date of the Agreement and arising from allegations of (A)&nbsp;breach of
fiduciary duty of the Company&#146;s directors relating to their approval of the Agreement, (B)&nbsp;false or
misleading public disclosure by the Company with respect to the Agreement or (C)&nbsp;other claims in
connection with the Contemplated Transactions in the case of each of clauses &#147;(A),&#148; &#147;(B)&#148; and &#147;(C)&#148;
in and of itself (it being understood, however, that the facts or circumstances giving rise to any
such allegations may be taken into account in determining whether there has been or would be a
Company Material Adverse Effect); (vii)&nbsp;Effects resulting from actions taken at Parent&#146;s express
direction, including actions taken pursuant to <U>Section&nbsp;5.6</U> solely to the extent made
pursuant to the Parent&#146;s express direction; or (viii)&nbsp;changes since the date of the Agreement in
applicable Legal Requirements, regulatory conditions or GAAP (it being agreed that notwithstanding
any of the foregoing, any termination of any ongoing clinical studies of PEP005 (ingenol mebutate)
for safety reasons in accordance with the protocol for such clinical studies&nbsp;or as a result of an
action by a Governmental Body would be considered to constitute a Company Material Adverse Effect).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Option Plan</B>. &#147;Company Option Plan&#148; means the Company&#146;s 2007 Incentive Award Plan, as
it may be amended from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Options</B>. &#147;Company Options&#148; means options to purchase shares of Company Common Stock
from the Company (whether granted by the Company pursuant to the Company Option Plan, assumed by
the Company, or otherwise), <I>provided, that, </I>the Company Warrants shall not be considered Company
Options for any purpose hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Owned IP</B>. &#147;Company Owned IP&#148; means all Intellectual Property Rights that are owned by
the Company and its Subsidiaries and that are used or contemplated to be used in the conduct of the
business of the Company and its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Preferred Stock</B>. &#147;Company Preferred Stock&#148; means the Preferred Stock, $0.001 par
value per share, of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Product</B>. &#147;Company Product&#148; means any product of any Acquired Corporation that, on a
stand-alone basis (a)&nbsp;has been manufactured, marketed, distributed, provided, leased, licensed or
sold by or on behalf of any Acquired Corporation at any time, (b)&nbsp;any Acquired Corporation
currently supports or is obligated to support or maintain or (c)&nbsp;is under development by or for any
Acquired Corporation (whether or not in collaboration with another
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Person), including the following products of the Company and its Subsidiaries: (a)&nbsp;PEP005
(ingenol mebutate) Gel for the treatment of actinic keratosis and (b)&nbsp;PEP005 (ingenol mebutate) Gel
for the treatment of superficial basal cell carcinoma.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Public Documents</B>. &#147;Company Public Documents&#148; means the Company ASX Documents and the
Company SEC Documents, collectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Registered IP</B>. &#147;Company Registered IP&#148; means all Registered IP owned by, or filed in
the name of, the Company or any of its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company SEC Documents</B>. &#147;Company SEC Documents&#148; means all proxy statements, reports,
schedules, forms, statements or other documents, including all amendments thereto, required to be
filed by the Company with or furnished by the Company to the SEC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Stockholders</B>. &#147;Company Stockholders&#148; means the holders of Company Common Stock and
Share CDIs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Triggering Event</B>. A &#147;Company Triggering Event&#148; shall be deemed to have occurred if:
(a)&nbsp; the Company Board shall have failed to recommend that the Company Stockholders vote to adopt
the Agreement, or withdraws or modifies in a manner adverse to Parent the Company Board
Recommendation; (b)&nbsp;the Company fails to include in the Proxy Statement, or shall have amended the
Proxy Statement to exclude, the Company Board Recommendation; (c)&nbsp;the Company Board fails to
reaffirm the Company Board Recommendation (publicly, if requested by Parent) within 10 Business
Days after Parent requests in writing that it be reaffirmed; (d)&nbsp;the Company Board approves,
endorses or recommends any Acquisition Proposal; (e)&nbsp;the Company enters into any letter of intent
or similar document or any Contract contemplating any Acquisition Proposal or enters into a binding
definitive agreement accepting an Acquisition Proposal; (e)&nbsp;a tender or exchange offer relating to
securities of the Company is commenced by a Person unaffiliated with Parent, and the Company has
not sent to the Company Stockholders, within ten (10)&nbsp;Business Days after the commencement of such
tender or exchange offer, a statement disclosing that the Company recommends rejection of such
tender or exchange offer; or (f)&nbsp;any of the Acquired Corporations or any Representative of any of
the Acquired Corporations shall have materially breached any of their obligations set forth in
<U>Section&nbsp;4.3</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Company Warrants</B>. &#147;Company Warrants&#148; means warrants to purchase shares of Company Common
Stock from the Company, including warrants in respect of which Option CDIs have been issued.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidentiality Agreement</B>. &#147;Confidentiality Agreement&#148; means that certain Confidentiality
Agreement dated as of February&nbsp;27, 2007, between Peplin Limited CAN 090 819 275 and Parent, as
amended by that certain Amendment No.&nbsp;1 to Confidentiality Agreement dated as of March&nbsp;10, 2009,
among the Company, Peplin Limited CAN 090 819 275 and Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Consent</B>. &#147;Consent&#148; means any approval, consent, ratification, permission, waiver or
authorization (including any Governmental Authorization).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Contemplated Transactions</B>. &#147;Contemplated Transactions&#148; means the Merger and the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">other transactions contemplated by the Agreement or the Voting Agreements.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Contract</B>. &#147;Contract&#148; means any written, oral or other agreement, contract, subcontract,
lease, legally binding understanding, legally binding arrangement, settlement, legally binding
instrument, note, option, warranty, purchase order, license, sublicense, insurance policy, legally
binding benefit plan or legally binding commitment or undertaking of any nature, whether express or
implied.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Corporations Act</B>. &#147;Corporations Act&#148; means the Australian Corporations Act 2001 (Cth), as
amended and the Corporations Regulations 2001 made under it.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>DGCL</B>. &#147;DGCL&#148; means the Delaware General Corporation Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Dissenting Shares</B>. &#147;Dissenting Shares&#148; means any shares of Company Common Stock that are
issued and outstanding immediately before the Effective Time and in respect of which the holder
thereof has made a proper demand for appraisal of such shares of Company Common Stock in accordance
with Section&nbsp;262 of the DGCL and has otherwise complied with all applicable provisions of Section
262 of the DGCL in connection with the Merger, provided that any such shares of Company Common
Stock shall cease to be Dissenting Shares hereunder after such time as such holder fails to perfect
or otherwise loses such holder&#146;s appraisal rights under Section&nbsp;262 of the DGCL with respect to
such shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Encumbrance</B>. &#147;Encumbrance&#148; means any lien, pledge, hypothecation, hypothecation, option,
right of first refusal, preemptive right, charge, mortgage, easement, encroachment, imperfection of
title, title exception, title defect, right of possession, lease, security interest, encumbrance,
adverse claim, interference, restriction on transfer (except for restrictions arising under
applicable securities laws) or other restriction of any nature except for Permitted Encumbrances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Entity</B>. &#147;Entity&#148; means any corporation (including any non-profit corporation), general
partnership, limited partnership, limited liability partnership, joint venture, estate, trust,
company (including any company limited by shares, limited liability company or joint stock
company), firm, society or other enterprise, association, organization or other entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ERISA</B>. &#147;ERISA&#148; means the Employee Retirement Income Security Act of 1974, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exchange Act</B>. &#147;Exchange Act&#148; means the Securities Exchange Act of 1934, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>FDA</B>. &#147;FDA&#148; means the United States Food and Drug Administration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>GAAP</B>. &#147;GAAP&#148; means generally accepted accounting principles in the United States.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Governmental Authorization</B>. &#147;Governmental Authorization&#148; means any permit, license,
certificate, franchise, permission, variance, clearance, registration, qualification or
authorization issued, granted, given or otherwise made available by or under the authority of any
Governmental Body or pursuant to any Legal Requirement, or right
under any Contract with any Governmental Body.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Governmental Body</B>. &#147;Governmental Body&#148; means any: (a)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state,
local, municipal, foreign or other government; (c)&nbsp;governmental or quasi-governmental authority of
any nature (including any governmental division, department, agency, commission, or
instrumentality, and any court or other tribunal); or (d)&nbsp;self-regulatory organization (including
the NASDAQ Stock Market LLC and FINRA-Financial Industry Regulatory Authority). For the avoidance
of doubt, Governmental Body shall include the Australian Takeovers Panel, the Australian Securities
Exchange, the Australian Securities and Investments Commission, the FDA and any other agency in the
world that is responsible for regulating or supervising the safety of foods, dietary supplements,
medical devices or drugs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>HSR Act</B>. &#147;HSR Act&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Intellectual Property</B>. &#147;Intellectual Property&#148; means formulae, inventions (whether or not
patentable), know-how, methods, processes, proprietary information, specifications, software,
techniques, URLs, web sites, works of authorship and other forms of technology.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Intellectual Property Rights</B>. &#147;Intellectual Property Rights&#148; means all rights of the
following types, which may exist or be created under the laws of any jurisdiction in the world: (a)
rights associated with works of authorship, including copyrights and
moral rights; (b)&nbsp;trademark, trade name and domain name rights and similar rights; (c)&nbsp;trade secret rights;
(d)&nbsp;patent and industrial property rights; (e)&nbsp;other proprietary and intangible rights in
Intellectual Property; and (f)&nbsp;rights in or relating to registrations, renewals, extensions,
combinations, divisions and reissues of, and applications for, any of the rights referred to in
clauses &#147;(a)&#148; through &#147;(e)&#148; above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Knowledge</B>. &#147;knowledge&#148; means, with respect to any party as to any particular matter, the
actual knowledge of the directors and officers of such party regarding such matter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Legal Proceeding</B>. &#147;Legal Proceeding&#148; means any action, suit, litigation, arbitration,
proceeding (including any civil, criminal, administrative, investigative or appellate proceeding),
hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or
before, or otherwise involving, any court or other Governmental Body or any arbitrator or
arbitration panel.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Legal Requirement</B>. &#147;Legal Requirement&#148; means any federal (including United States, Australian
and Irish), state, local, municipal, foreign or other law, statute, constitution, principle of
common law, resolution, ordinance, code, edict, decree, rule, regulation, order, award, stock
exchange rule, ruling or requirement issued, enacted, adopted, promulgated, implemented or
otherwise put into effect by or under the authority of any Governmental Body (or under the
authority of the ASX).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Option CDIs</B>. &#147;Option CDIs&#148; means CHESS Depositary Interests representing options to purchase
shares of Company Common Stock (in the ratio of one (1)&nbsp;option to purchase one (1)&nbsp;share of Company
Common Stock to twenty (20)&nbsp;Option CDIs) (ASX: PLIO).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Order</B>. &#147;Order&#148; means any order, writ, injunction, judgment or decree.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Parent Disclosure Schedule</B>. &#147;Parent Disclosure Schedule&#148; means the Parent Disclosure Schedule
and exhibits thereto that Parent delivers to the Company upon the execution of the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Parent Material Adverse Effect</B>. &#147;Parent Material Adverse Effect&#148; means any Effect that,
considered together with all other Effects, would reasonably be expected to have a material adverse
effect on the ability of Parent to consummate the Merger; <I>provided, however, </I>that, in no event
shall any of the following, alone or in combination, be deemed to constitute, nor shall any of the
following be taken into account in determining whether there has occurred, a Parent Material
Adverse Effect: (i)&nbsp;Effects resulting from changes since the date of the Agreement in conditions,
including regulatory review standards, generally affecting the industries in which Parent or any of
its Subsidiaries participates or the U.S. or global economy or capital markets as a whole, to the
extent that such changed conditions do not have a substantially disproportionate impact on Parent
and its Subsidiaries taken as a whole when compared to other firms in the industries in which
Parent or any of its Subsidiaries participates; (ii)&nbsp;Effects resulting from acts of war, armed
hostilities or terrorism since the date of the Agreement; (iii)&nbsp;Effects resulting from the
announcement or pendency of the Merger and the Contemplated Transactions to the extent that Parent
conclusively demonstrates that such Effects are directly and exclusively attributable to the
announcement or pendency of the Merger and the Contemplated Transactions; (iv)&nbsp;Company stockholder
class action or derivative litigation commenced against Parent since the date of the Agreement and
arising from allegations of breach of fiduciary duty of the Company&#146;s directors relating to their
approval of the Agreement or from allegations of false or misleading public disclosure by Parent
with respect to the Agreement; or (vii)&nbsp;changes since the date of the Agreement in applicable Legal
Requirements, regulatory conditions or GAAP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Permitted Encumbrance</B>. &#147;Permitted Encumbrance&#148; means: (a)&nbsp;liens, licenses that are listed on
the Company Disclosure Schedule, exceptions, security interests, restrictions, imperfections of
title or other similar matters that have arisen in the ordinary course of business and that do not
and would not be reasonably likely to, individually or in the aggregate, materially detract from
the value of the property subject thereto or materially interfere with the ordinary conduct of the
business of any of the Acquired Corporations; (b)&nbsp;Encumbrances for current Taxes, assessments or
other government charges not yet due; (c)&nbsp;zoning, building or other similar government
restrictions; (d)&nbsp;easements, covenants, rights of way or other similar restrictions with respect to
real property; and (e)&nbsp;liens securing indebtedness that is reflected on the Company Unaudited
Balance Sheet.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Person</B>. &#147;Person&#148; means any individual, Entity or Governmental Body.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Registered IP</B>. &#147;Registered IP&#148; means all Intellectual Property Rights that are registered,
applied for, filed, perfected, issued or recorded with or by any Governmental Body.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Representatives</B>. &#147;Representatives&#148; means directors, officers, agents, attorneys, accountants,
advisors and representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Required Company Stockholder Vote</B>. &#147;Required Company Stockholder Vote&#148; means
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the affirmative vote of the Company Stockholders holding at least a majority of the
outstanding shares of Company Common Stock in favor of the adoption of the Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Sarbanes-Oxley Act</B>. &#147;Sarbanes-Oxley Act&#148; shall mean the Sarbanes-Oxley Act of 2002, as it may
be amended from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>SEC</B>. &#147;SEC&#148; means the United States Securities and Exchange Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Securities Act</B>. &#147;Securities Act&#148; means the Securities Act of 1933, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Share CDIs</B>. &#147;Share CDIs&#148; means CHESS Depositary Interests representing shares of Company
Common Stock (in the ratio of one (1)&nbsp;share of Company Common Stock to twenty (20)&nbsp;Share CDIs)
(ASX: PLI).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Subsidiary</B>. An Entity shall be deemed to be a &#147;Subsidiary&#148; of another Person if such Person
directly or indirectly owns or purports to own, beneficially or of record: (a)&nbsp;an amount of voting
securities of or other interests in such Entity that is sufficient to enable such Person to elect
at least a majority of the members of such Entity&#146;s board of directors or other governing body; or
(b)&nbsp;at least 50% of the outstanding equity, voting or financial interests in such Entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Superior Offer</B>. &#147;Superior Offer&#148; means an unsolicited bona fide, written offer by a third
party to acquire, directly or indirectly, pursuant to a tender offer, exchange offer, merger,
consolidation or other business combination, all or substantially all of the assets of the Acquired
Corporations, taken as a whole or in excess of 50% of the outstanding voting securities of the
Company and as a result of which the Company Stockholders immediately preceding such transaction
would cease to hold at least 50% of the equity interests in the surviving or resulting entity of
such transaction or any direct or indirect parent or subsidiary thereof, that (a)&nbsp;was not obtained
or made as a direct or indirect result of a breach by the Company of the Agreement or the
Confidentiality Agreement, (b)&nbsp;is determined by the Company Board, in its good faith judgment,
after consultation with an independent financial advisor of nationally recognized reputation, and
after taking into account the likelihood and anticipated timing of consummation, to be more
favorable from a financial point of view to the Company Stockholders than the Merger and (c)
contemplates a transaction that is reasonably capable of being consummated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax</B>. &#147;Tax&#148; means any federal, state, local, or foreign tax (including any income, franchise,
capital gains, gross receipts, value-added, surtax, estimated, unemployment, national health
insurance, excise, ad valorem, transfer, stamp, sales, use, property, custom duty, withholding or
payroll tax), including any penalty, interest or addition thereto), imposed by or under the
authority of any Governmental Body.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax Return</B>. &#147;Tax Return&#148; means any return (including any information return), report,
statement, declaration or other document (including any schedule or attachment thereto, and
including any amendment thereof) required to be filed with any Governmental Body with respect to
Taxes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>TGA</B>. &#147;TGA&#148; means the Australian Therapeutic Goods Administration.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->A-9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;B</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Form of Certificate of Merger</B></FONT>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->B-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATE OF MERGER</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>OF</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PLANT ACQUISITION SUB, INC.</B><BR>
(a Delaware corporation)

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>WITH AND INTO</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PEPLIN, INC.</B><BR>
(a Delaware corporation)

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Pursuant to Section&nbsp;251 of the<BR>
General Corporation Law of the State of Delaware

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV><BR>
&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;, 2009

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peplin, Inc., a Delaware corporation (&#147;<B><I>Peplin</I></B>&#148;), does hereby certify to the following facts
relating to the merger of Plant Acquisition Sub, Inc., a Delaware corporation (&#147;<B><I>Sub</I></B>&#148;), with and
into Peplin, pursuant to the provisions of Section&nbsp;251 of the General Corporation Law of the State
of Delaware:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The name and the state of incorporation of each of the constituent corporations (the
&#147;<B><I>Constituent Corporations</I></B>&#148;) are as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Name</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">State of Incorporation</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plant Acquisition Sub, Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Delaware</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Peplin, Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Delaware</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;An Agreement and Plan of Merger, dated as of September&nbsp;2, 2009 (the &#147;<B><I>Agreement</I></B>&#148;), setting
forth the terms and conditions of the merger of Sub with and into Peplin (the &#147;<B><I>Merger</I></B>&#148;), has been
approved, adopted, executed, and acknowledged by both of the Constituent Corporations in accordance
with the requirements of Section&nbsp;251 of the General Corporation Law of the State of Delaware.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;Peplin shall be the surviving corporation in the Merger (the &#147;<B><I>Surviving Corporation</I></B>&#148;). The
name of the Surviving Corporation shall be Peplin, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Upon the effectiveness of the Certificate of Incorporation of the Surviving Corporation
shall be amended and restated to read in its entirety as set forth in <U>Exhibit&nbsp;A</U> attached
hereto.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->B-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;The executed Agreement is on file at the principal place of business of the Surviving
Corporation. The address of the principal place of business of the Surviving Corporation is 6475
Christie Avenue, Suite&nbsp;300, Emeryville, California 94608.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;A copy of the Agreement will be furnished by the Surviving Corporation, on request and
without cost, to any stockholder of either Constituent Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;This Certificate of Merger and the Merger shall become effective at the time this
Certificate of Merger is filed with the Secretary of State of the State of Delaware.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>&#091;Remainder of Page Intentionally Left Blank&#093;</B></FONT>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->B-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>In Witness Whereof</B></FONT>, Peplin, Inc. has caused this <FONT style="font-variant: SMALL-CAPS"><B>Certificate of Merger</B></FONT> to be
executed by the undersigned, its authorized officer, as of the date first written above
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Peplin, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>&#091;Signature Page to Certificate of Merger&#093;</B></font>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->B-4<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibits</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;A  &#151;  Certain Definitions
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;B  &#151;  Form of Certificate of Merger
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
